NO912385L - Chimere immunoglobuliner som er spesifikke for p55 tac proteiner av il-2 reseptoren. - Google Patents
Chimere immunoglobuliner som er spesifikke for p55 tac proteiner av il-2 reseptoren.Info
- Publication number
- NO912385L NO912385L NO91912385A NO912385A NO912385L NO 912385 L NO912385 L NO 912385L NO 91912385 A NO91912385 A NO 91912385A NO 912385 A NO912385 A NO 912385A NO 912385 L NO912385 L NO 912385L
- Authority
- NO
- Norway
- Prior art keywords
- human
- receptor
- tac
- cdr
- chimering
- Prior art date
Links
- 102000010789 Interleukin-2 Receptors Human genes 0.000 title abstract 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 4
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 102000055277 human IL2 Human genes 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29097588A | 1988-12-28 | 1988-12-28 | |
| US31025289A | 1989-02-13 | 1989-02-13 | |
| PCT/US1989/005857 WO1990007861A1 (en) | 1988-12-28 | 1989-12-28 | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO912385L true NO912385L (no) | 1991-06-19 |
| NO912385D0 NO912385D0 (no) | 1991-06-19 |
| NO310473B1 NO310473B1 (no) | 2001-07-09 |
Family
ID=26966505
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19912385A NO310473B1 (no) | 1988-12-28 | 1991-06-19 | Fremgangsmåte for fremstilling av humanisert immunoglobulin, polynukleotid som koder for nevnte immunoglobulin og cellelinjesom er transfektert med nevnte polynukleotid |
| NO2001026C NO2001026I2 (no) | 1988-12-28 | 2001-12-17 | Daclizumab |
| NO2001024C NO2001024I1 (no) | 1988-12-28 | 2001-12-17 | Trastuzumab eller farmasøytiske akseptable salter derav |
| NO2001025C NO2001025I2 (no) | 1988-12-28 | 2001-12-17 | Palivizumab |
| NO2005005C NO2005005I2 (no) | 1988-12-28 | 2005-02-18 | Bevacizumab eller farmasoeytisk akseptable salter derav |
| NO2005026C NO2005026I2 (no) | 1988-12-28 | 2005-12-07 | Omalizumab eller farmasoeytisk akseptable salter derav |
| NO2006009C NO2006009I2 (no) | 1988-12-28 | 2006-08-07 | Natalizumab eller farmasoytisk akseptable salter derav |
| NO2007006C NO2007006I2 (no) | 1988-12-28 | 2007-04-18 | Ranibizumab eller farmasoytisk akseptable salter derav |
| NO2009026C NO2009026I1 (no) | 1988-12-28 | 2009-11-12 | Certolizumab pegol |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2001026C NO2001026I2 (no) | 1988-12-28 | 2001-12-17 | Daclizumab |
| NO2001024C NO2001024I1 (no) | 1988-12-28 | 2001-12-17 | Trastuzumab eller farmasøytiske akseptable salter derav |
| NO2001025C NO2001025I2 (no) | 1988-12-28 | 2001-12-17 | Palivizumab |
| NO2005005C NO2005005I2 (no) | 1988-12-28 | 2005-02-18 | Bevacizumab eller farmasoeytisk akseptable salter derav |
| NO2005026C NO2005026I2 (no) | 1988-12-28 | 2005-12-07 | Omalizumab eller farmasoeytisk akseptable salter derav |
| NO2006009C NO2006009I2 (no) | 1988-12-28 | 2006-08-07 | Natalizumab eller farmasoytisk akseptable salter derav |
| NO2007006C NO2007006I2 (no) | 1988-12-28 | 2007-04-18 | Ranibizumab eller farmasoytisk akseptable salter derav |
| NO2009026C NO2009026I1 (no) | 1988-12-28 | 2009-11-12 | Certolizumab pegol |
Country Status (32)
| Country | Link |
|---|---|
| EP (6) | EP1491556B1 (no) |
| JP (6) | JP2828340B2 (no) |
| KR (1) | KR0178385B1 (no) |
| CN (1) | CN1057013C (no) |
| AT (2) | ATE183753T1 (no) |
| AU (1) | AU647383B2 (no) |
| BG (1) | BG61095B2 (no) |
| CA (2) | CA2006865C (no) |
| CZ (1) | CZ418691A3 (no) |
| DD (1) | DD296964A5 (no) |
| DE (14) | DE122005000007I2 (no) |
| DK (2) | DK119191A (no) |
| ES (5) | ES2136760T3 (no) |
| FI (1) | FI108797B (no) |
| FR (1) | FR14C0070I1 (no) |
| HK (1) | HK1014718A1 (no) |
| HR (1) | HRP920500B1 (no) |
| HU (1) | HU211174A9 (no) |
| IE (1) | IE20000331A1 (no) |
| IL (2) | IL162181A (no) |
| LU (8) | LU90411I2 (no) |
| MC (1) | MC2146A1 (no) |
| NL (8) | NL990020I2 (no) |
| NO (9) | NO310473B1 (no) |
| NZ (2) | NZ314793A (no) |
| PT (1) | PT92758B (no) |
| RU (1) | RU2126046C1 (no) |
| SG (1) | SG78258A1 (no) |
| SI (1) | SI8912489B (no) |
| WO (1) | WO1990007861A1 (no) |
| YU (1) | YU48700B (no) |
| ZA (1) | ZA899956B (no) |
Families Citing this family (966)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800815A (en) * | 1903-05-05 | 1998-09-01 | Cytel Corporation | Antibodies to P-selectin and their uses |
| US5851526A (en) * | 1985-04-19 | 1998-12-22 | Ludwig Institute For Cancer Research | Methods of treating colon cancer utilizing tumor-specific antibodies |
| US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7247453B1 (en) * | 1988-12-30 | 2007-07-24 | Oklahoma Medical Research Foundation | Calcium binding recombinant antibody against protein C |
| DE3900534A1 (de) * | 1989-01-10 | 1990-07-12 | Boehringer Mannheim Gmbh | Diagnostischer nachweis unter verwendung von chimaeren antikoerpern |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| GR1001050B (el) * | 1990-01-09 | 1993-04-28 | Protein Design Labs Inc | Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων. |
| HUT60768A (en) | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
| GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| US5858725A (en) * | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
| US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
| JP3854306B2 (ja) * | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ヒト化及びキメラモノクローナル抗体 |
| NZ241855A (en) * | 1991-03-07 | 1994-04-27 | Gen Hospital Corp | Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor |
| DE69226431T2 (de) * | 1991-04-05 | 1999-04-22 | Univ Washington | Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor |
| RU2139351C1 (ru) * | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
| EP0519596B1 (en) * | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| CA2103059C (en) * | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| GB9115010D0 (en) * | 1991-07-11 | 1991-08-28 | Wellcome Found | Antibody |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| MX9204374A (es) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5709860A (en) * | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
| US5756096A (en) * | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| US5585103A (en) * | 1991-07-25 | 1996-12-17 | Idec Pharmaceutical Corporation | Induction of cytotoxic T-lymphocyte responses |
| US6329509B1 (en) | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
| US6685939B2 (en) | 1991-08-14 | 2004-02-03 | Genentech, Inc. | Method of preventing the onset of allergic disorders |
| EP0528767B1 (en) * | 1991-08-21 | 2000-01-12 | Novartis AG | Antibody derivatives |
| GB9120467D0 (en) * | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| JP3024311B2 (ja) * | 1991-10-03 | 2000-03-21 | 味の素株式会社 | Ｉｌ−２受容体重鎖に結合するポリペプチド |
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
| US5817310A (en) * | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
| JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| EP1291360A1 (en) * | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5869619A (en) * | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5777085A (en) * | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
| EP0625200B1 (en) * | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
| GB9203459D0 (en) * | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5387676A (en) * | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| US6129914A (en) * | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| US6033667A (en) * | 1992-05-05 | 2000-03-07 | Cytel Corporation | Method for detecting the presence of P-selectin |
| US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5958708A (en) * | 1992-09-25 | 1999-09-28 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US6066718A (en) * | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| GB9223377D0 (en) * | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| ATE236987T1 (de) * | 1992-11-13 | 2003-04-15 | Idec Pharma Corp | Konsensus-kozak-sequenzen zur säugetier- exprimierung |
| US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5648267A (en) * | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| PL174721B1 (pl) | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
| US5804187A (en) * | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
| DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
| US5730979A (en) * | 1993-03-05 | 1998-03-24 | Universite Catholique Delouvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
| US5951983A (en) * | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
| US5817311A (en) * | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
| WO1994025067A1 (en) * | 1993-05-04 | 1994-11-10 | Cytel Corporation | Antibodies to p-selectin and their uses |
| AU695124B2 (en) | 1993-05-28 | 1998-08-06 | Scripps Research Institute, The | Methods and compositions for inhibiting CD14 mediated cell activation |
| TW458985B (en) * | 1993-05-31 | 2001-10-11 | Chugai Pharmaceutical Co Ltd | Reconstructed human antibody against human interleukin-6 |
| US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US20020193575A1 (en) | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US5928904A (en) * | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US5914110A (en) * | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| NZ274338A (en) * | 1993-09-07 | 1998-02-26 | Smithkline Beecham Corp | Chimeric and humanised il-4 monoclonal antibodies and their use |
| AU7949394A (en) | 1993-11-19 | 1995-06-06 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human medulloblastomatous cell |
| WO1995015181A1 (en) * | 1993-11-30 | 1995-06-08 | Protein Design Labs, Inc. | Reperfusion therapy using antibodies to l-selectin |
| GB9325182D0 (en) * | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
| US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| ES2270425T3 (es) * | 1994-01-25 | 2007-04-01 | Elan Pharmaceuticals, Inc. | Anticuerpos humanizados contra la molecula de adhesion leucocitaria vla-4. |
| WO1995026403A1 (en) | 1994-03-29 | 1995-10-05 | Celltech Therapeutics Limited | Antibodies against e-selectin |
| US5635597A (en) * | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
| US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
| GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| USRE39548E1 (en) * | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
| US6048972A (en) * | 1994-07-13 | 2000-04-11 | Chugai Pharmaceutical Co., Ltd. | Recombinant materials for producing humanized anti-IL-8 antibodies |
| DE4425115A1 (de) * | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Verfahren zur Modifizierung der Stabilität von Antikörpern |
| EP0696455A1 (en) * | 1994-08-11 | 1996-02-14 | Cellena (Cell Engineering) A.G. | Transferrin compositions to alleviate the side effects of cytotoxic drugs |
| US8771694B2 (en) * | 1994-08-12 | 2014-07-08 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
| US5707621A (en) * | 1994-08-31 | 1998-01-13 | Chugai Pharmaceutical Co., Ltd. | Supression of nephritis-induced protein excretion by anti-IL-8 |
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| US5683892A (en) * | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
| US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| AU6171196A (en) * | 1995-06-07 | 1996-12-30 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of ta99 |
| US7153508B2 (en) | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| GB9600660D0 (en) | 1996-01-12 | 1996-03-13 | Ciba Geigy Ag | Protein |
| WO1997033617A1 (en) * | 1996-03-13 | 1997-09-18 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
| US5882644A (en) * | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
| US6713305B1 (en) | 1996-04-29 | 2004-03-30 | Novartis Ag | Metastasis-associated antigen and antibodies thereto |
| CA2257357C (en) | 1996-06-07 | 2010-04-13 | Neorx Corporation | Humanized antibodies with modified glycosylation |
| US6534311B2 (en) | 1996-07-24 | 2003-03-18 | Novartis Ag | Drosophila melanogaster p70S6 kinase |
| US6833255B1 (en) | 1996-07-24 | 2004-12-21 | Novartis, Ag | Drosophila melanogaster p70 S6 kinase |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| CA2264968A1 (en) * | 1996-09-02 | 1998-03-12 | Sumitomo Electric Industries, Ltd. | Humanized immunoglobulin reacting specifically with fas ligand or active fragments thereof and region inducing apoptosis originating in fas ligand |
| US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| CN100335501C (zh) | 1996-09-26 | 2007-09-05 | 中外制药株式会社 | 抗人副甲状腺激素相关蛋白的抗体 |
| UA76934C2 (en) | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
| US7883872B2 (en) | 1996-10-10 | 2011-02-08 | Dyadic International (Usa), Inc. | Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose |
| US20020160005A1 (en) | 1996-11-15 | 2002-10-31 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic urmec syndrome |
| US7910096B2 (en) | 1996-11-15 | 2011-03-22 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic uremic syndrome |
| EP2314695A3 (en) | 1996-12-23 | 2011-12-21 | Immunex Corporation | Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily |
| US6262238B1 (en) * | 1997-01-14 | 2001-07-17 | Roche Diagnostic, Gmbh | Process for modifying the stability of antibodies |
| US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
| US6596850B1 (en) | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
| US5986065A (en) | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US20060235209A9 (en) | 1997-03-10 | 2006-10-19 | Jin-An Jiao | Use of anti-tissue factor antibodies for treating thromboses |
| US20030109680A1 (en) | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US7749498B2 (en) | 1997-03-10 | 2010-07-06 | Genentech, Inc. | Antibodies for inhibiting blood coagulation and methods of use thereof |
| IL123756A0 (en) * | 1997-03-21 | 1998-10-30 | Sankyo Co | Humanized anti-human FAS antibody |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| SK155799A3 (en) | 1997-05-15 | 2000-06-12 | Chugai Pharmaceutical Co Ltd | Cachexia remedy |
| ES2258817T3 (es) * | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| EP1019082B2 (en) | 1997-10-02 | 2008-06-04 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| BR9812846A (pt) | 1997-10-03 | 2000-08-08 | Chugai Pharmaceutical Co Ltd | Anticorpo humanizado natural |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| EP1745799B1 (en) | 1998-03-04 | 2015-09-02 | The Trustees of The University of Pennsylvania | Compositions and methods of treating tumors |
| PL343322A1 (en) | 1998-04-03 | 2001-08-13 | Chugai Pharmaceutical Co Ltd | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
| DK1974747T3 (da) | 1998-08-11 | 2012-09-17 | Biogen Idec Inc | Kombinationsterapier for B-celle-lymfomer omfattende indgivelse af anti-CD20-antistof |
| JP4689781B2 (ja) * | 1998-09-03 | 2011-05-25 | 独立行政法人科学技術振興機構 | アミノ酸輸送蛋白及びその遺伝子 |
| PT1113810E (pt) | 1998-09-14 | 2009-03-10 | Univ Texas | Processos de tratamento de mieloma múltiplo e reabsorção óssea induzida por mieloma utilizando antagonistas da ligação do receptor de integrina |
| EA005682B1 (ru) | 1998-10-06 | 2005-04-28 | Марк Аарон Эмалфарб | Трансформированные грибы, в частности рода chrysosporium, способные к синтезу гетерологичных полипептидов |
| EP1939215A1 (en) | 1998-10-22 | 2008-07-02 | The University of Montana | Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof |
| KR20010103655A (ko) | 1998-11-09 | 2001-11-23 | 케네쓰 제이. 울코트 | 키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와관련된 혈액학적 악성종양의 치료법 |
| GB9825632D0 (en) | 1998-11-23 | 1999-01-13 | Novartis Ag | Organic compounds |
| US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
| WO2000051628A2 (en) | 1999-03-03 | 2000-09-08 | Biogen, Inc. | Methods of modulating lipid metabolism and storage |
| GB9906380D0 (en) * | 1999-03-19 | 1999-05-12 | Melvin William T | Monoclonal antibodies specific for cypibi |
| SK287328B6 (sk) | 1999-04-22 | 2010-07-07 | Biogen Idec Ma Inc. | Použitie kompozície obsahujúcej homológ protilátky, ktorý je antagonistom interakcie medzi integrínom nesúcim podjednotku alfa4 a ligandom pre integrín nesúci podjednotku alfa4 |
| IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| SI1488806T1 (sl) | 1999-06-01 | 2016-02-29 | Biogen Ma Inc. | Blokirno monoklonsko protitelo proti vla-1 in njegova uporaba za zdravljenje žilnih obolenj |
| US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
| US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
| TWI255718B (en) | 1999-07-02 | 2006-06-01 | Chugai Pharmaceutical Co Ltd | Ameliorative agent for low vasopressin concentration |
| US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
| ES2301491T3 (es) * | 1999-09-30 | 2008-07-01 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo humano de trasplante con region de determinacion de la complementariedad contra gangliosido gd3 y derivados del anticuerpo contra gangliosido gd3. |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| CA2392477A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| JP2003517023A (ja) | 1999-12-16 | 2003-05-20 | バイオジェン インコーポレイテッド | 中枢神経系の虚血性損傷または出血性損傷を、抗α４インテグリンアンタゴニストを用いて処置する方法 |
| ES2349348T3 (es) | 2000-01-27 | 2010-12-30 | Medimmune, Llc | Anticuerpos neutralizantes de rsv de ultra alta afinidad. |
| AU2001233277B2 (en) * | 2000-02-03 | 2004-06-03 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
| AU3495301A (en) | 2000-02-11 | 2001-08-20 | Biogen Inc | Heterologous polypeptide of the tnf family |
| EP3070100B1 (en) | 2000-02-24 | 2021-07-07 | Washington University St. Louis | Humanized antibodies that sequester amyloid beta peptide |
| ES2390761T3 (es) | 2000-03-01 | 2012-11-16 | Medimmune, Llc | Anticuerpos recombinantes de alta potencia y método para producción de los mismos |
| EP1267926A2 (en) | 2000-03-17 | 2003-01-02 | Millennium Pharmaceuticals, Inc. | Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| EP1283057B2 (en) | 2000-04-28 | 2012-05-30 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitors |
| US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| DE60136272D1 (de) | 2000-04-29 | 2008-12-04 | Univ Iowa Res Found | Diagnostika und therapeutika für makula degeneration erkrankungen |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| US7476383B2 (en) | 2000-05-02 | 2009-01-13 | The Uab Research Foundation | Antibody selective for DR4 and uses thereof |
| TWI318983B (en) * | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| PT1326896E (pt) | 2000-10-02 | 2011-03-03 | Novartis Vaccines & Diagnostic | Anticorpos humanos anti-cd40 |
| US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US6989247B2 (en) | 2000-11-28 | 2006-01-24 | Celltech R & D, Inc. | Compositions and methods for diagnosing or treating psoriasis |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| ES2314067T3 (es) * | 2001-04-06 | 2009-03-16 | University Of Bristol | Uso de moleculas de enlace cd 25 en pacientes resistentes a los esteroides. |
| ES2347532T3 (es) | 2001-04-13 | 2010-11-02 | Biogen Idec Ma Inc. | Anticuerpos contra vla-1. |
| EE200300569A (et) * | 2001-05-18 | 2004-04-15 | Boehringer Ingelheim International Gmbh | CD44v6-spetsiifilised antikehad |
| US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
| US7541443B2 (en) * | 2001-06-14 | 2009-06-02 | Tolerrx, Inc. | Anti-CD4 antibodies |
| WO2002102972A2 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20030013081A1 (en) | 2001-06-26 | 2003-01-16 | Olson William C. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| JP4675512B2 (ja) * | 2001-07-10 | 2011-04-27 | 三井化学株式会社 | 熱殺菌方法 |
| CA2454358A1 (en) | 2001-07-19 | 2003-07-31 | Perlan Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
| EP1420032B2 (en) | 2001-08-03 | 2015-12-16 | Medical & Biological Laboratories Co., Ltd. | Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody |
| EP1944040B1 (en) | 2001-08-17 | 2012-08-01 | Washington University | Assay method for Alzheimer's disease |
| CA2458811C (en) | 2001-09-20 | 2011-05-10 | Immunex Corporation | Selection of cells expressing heteromeric polypeptides |
| JPWO2003027151A1 (ja) | 2001-09-25 | 2005-01-06 | 株式会社 免疫生物研究所 | 組換え抗オステオポンチン抗体およびその用途 |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| US20030190705A1 (en) * | 2001-10-29 | 2003-10-09 | Sunol Molecular Corporation | Method of humanizing immune system molecules |
| CN1585778A (zh) * | 2001-11-12 | 2005-02-23 | 默克专利有限公司 | 修饰的抗－TNFα抗体 |
| PL209133B1 (pl) | 2001-11-21 | 2011-07-29 | Univ Pennsylvania | Rekombinowany adenowirus, obejmująca go izolowana komórka gospodarza, oraz kompozycja i zastosowanie |
| EP1944043A1 (en) | 2001-11-21 | 2008-07-16 | The Trustees of the University of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| EP2990394A1 (en) | 2001-11-30 | 2016-03-02 | Biogen MA Inc. | Antibodies against monocyte chemotactic proteins |
| SI1461428T1 (sl) * | 2001-12-03 | 2012-07-31 | Alexion Pharma Inc | Postopek za proizvodnjo hibridnih protiteles |
| US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| JP4498746B2 (ja) * | 2002-02-14 | 2010-07-07 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ２０抗体およびその融合タンパク質ならびに使用法 |
| EP2058006A1 (en) * | 2002-02-22 | 2009-05-13 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
| MXPA04008267A (es) | 2002-02-25 | 2004-11-10 | Elan Pharm Inc | Administracion de agentes para el tratamiento de la inflamacion. |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| BRPI0308585B8 (pt) | 2002-03-13 | 2021-05-25 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna |
| WO2003080674A1 (en) | 2002-03-20 | 2003-10-02 | Pharmacia Corporation | Antibody disulfide isomers, use thereof, and methods of analyzing same |
| EP1576013A4 (en) | 2002-03-22 | 2008-08-13 | Amrad Operations Pty Ltd | MONOCLONAL ANTIBODY AGAINST THE INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13RA1) |
| GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| US7202067B2 (en) | 2002-05-14 | 2007-04-10 | Martek Biosciences Corporation | Carotene synthase gene and uses therefor |
| ATE518885T1 (de) | 2002-05-28 | 2011-08-15 | Ucb Pharma Sa | Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870) |
| US7351803B2 (en) * | 2002-05-30 | 2008-04-01 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| WO2003106485A1 (en) | 2002-06-14 | 2003-12-24 | Monier Tadros | Method for the production of protamine |
| GB0213745D0 (en) | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
| US7575742B2 (en) | 2002-06-28 | 2009-08-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist |
| US9535076B2 (en) | 2002-09-12 | 2017-01-03 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
| US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| JP4966497B2 (ja) | 2002-11-15 | 2012-07-04 | ゲンマブ エー／エス | Ｃｄ２５に対するヒトモノクローナル抗体 |
| EP1660535A2 (en) | 2002-11-27 | 2006-05-31 | Minerva Biotechnologies Corporation | Techniques and compositions for the diagnosis and treatment of cancer (muc1) |
| RS51318B (sr) | 2002-12-16 | 2010-12-31 | Genentech Inc. | Varijante imunoglobulina i njihova upotreba |
| AU2004205684A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| MXPA05007843A (es) | 2003-01-24 | 2005-10-18 | Elan Pharm Inc | Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes. |
| EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
| US7321065B2 (en) | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
| EP2404615A1 (en) | 2003-04-23 | 2012-01-11 | Medarex, Inc. | Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) |
| ES2313039T3 (es) | 2003-04-23 | 2009-03-01 | Medarex, Inc. | Composiciones y procedimientos para la terapia de enfermedad inflamatoria intestinal. |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| DK2361928T3 (en) | 2003-05-19 | 2017-07-03 | Prothena Biosciences Ltd | Truncated fragments of alpha synuclein in Lewy body disease |
| CA2528551A1 (en) | 2003-06-13 | 2005-01-13 | Biogen Idec Ma Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| US8153410B2 (en) | 2003-07-07 | 2012-04-10 | Fox Chase Cancer Center | Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules |
| US20060162014A1 (en) | 2003-07-07 | 2006-07-20 | Jaffe Eileen K | Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules |
| PL1641822T3 (pl) | 2003-07-08 | 2013-10-31 | Genentech Inc | Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne |
| NZ544797A (en) | 2003-07-18 | 2011-04-29 | Amgen Fremont Inc | Specific antibodies that bind HGF and neutralise binding of HGF to met |
| US7834155B2 (en) | 2003-07-21 | 2010-11-16 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
| US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
| GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| AU2004287722A1 (en) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-CD47 antibody |
| WO2005047481A2 (en) | 2003-11-12 | 2005-05-26 | Progenics Pharmaceuticals, Inc. | Novel sequences encoding hapatitis c virus glycoproteins |
| JP4898452B2 (ja) | 2003-12-05 | 2012-03-14 | マルチミューン ジーエムビーエイチ | 治療および診断用抗Ｈｓｐ７０抗体 |
| US7332584B2 (en) | 2003-12-08 | 2008-02-19 | Morphotek, Inc. | Antibodies that specifically bind PMS2 |
| US20080025913A1 (en) | 2003-12-15 | 2008-01-31 | Bowdish Katherine S | Novel Anti-Dc-Sign Antibodies |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| HUE039803T2 (hu) | 2004-01-07 | 2019-02-28 | Novartis Vaccines & Diagnostics Inc | M-CSF-specifikus monoklonális ellenanyag és alkalmazásai |
| EP1712566A4 (en) | 2004-01-19 | 2007-09-12 | Medical & Biol Lab Co Ltd | INFLAMMATORY CYTOKINE INHIBITOR |
| WO2005081783A2 (en) | 2004-01-30 | 2005-09-09 | Dana Farber Cancer Institute | Method for determination and quantification of radiation or genotoxin exposure |
| EP2340850A1 (en) | 2004-02-10 | 2011-07-06 | The Regents of the University of Colorado, a Body Corporate | Inhibition of factor B, the alternative complement pathway and methods related thereto |
| EP2316857A1 (en) | 2004-02-12 | 2011-05-04 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| TWI359026B (en) | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
| JP4824547B2 (ja) | 2004-02-20 | 2011-11-30 | インテレクト ニュウロサイエンシス，インク． | モノクローナル抗体およびその利用 |
| NZ549787A (en) | 2004-03-12 | 2010-05-28 | Vasgene Therapeutics Inc | Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth |
| US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
| MXPA06010673A (es) | 2004-03-19 | 2007-06-20 | Amgen Inc | Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v. |
| MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| AU2005229015C1 (en) | 2004-04-02 | 2013-01-17 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
| CA2568201C (en) | 2004-05-24 | 2013-07-30 | Universitat Zu Koln | Identification of ergothioneine transporter and therapeutic uses thereof |
| EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
| RU2600884C2 (ru) | 2004-06-21 | 2016-10-27 | Е. Р. Сквибб энд Сонз, Эл,Эл.Си | Антитела рецептора 1 интерферона альфа и их применение |
| GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
| AU2005287406B2 (en) | 2004-07-26 | 2011-08-18 | Biogen Ma Inc. | Anti-CD154 antibodies |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| FI20041204A0 (fi) | 2004-09-16 | 2004-09-16 | Riikka Lund | Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi |
| AU2005291486A1 (en) | 2004-10-01 | 2006-04-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Novel antibodies directed to the mammalian EAG1 ion channel protein |
| MX2007004176A (es) | 2004-10-06 | 2007-06-15 | Mayo Foundation | B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer. |
| KR101370253B1 (ko) | 2004-10-22 | 2014-03-05 | 암젠 인크 | 재조합 항체의 재접힘 방법 |
| EP1812062B1 (en) | 2004-10-25 | 2022-03-09 | Merck Sharp & Dohme Corp. | Anti-addl antibodies and uses thereof |
| CA2587597A1 (en) | 2004-11-19 | 2006-05-26 | Biogen Idec Ma Inc. | Treatment for multiple sclerosis |
| PE20061329A1 (es) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
| CA2594356C (en) | 2005-01-05 | 2018-07-17 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| CA2590974C (en) | 2005-01-27 | 2017-10-03 | Children's Hospital & Research Center At Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| US8088579B2 (en) | 2005-02-14 | 2012-01-03 | University Of Iowa Research Foundation | Complement factor H for diagnosis of age-related macular degeneration |
| WO2006089095A2 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
| JP4942644B2 (ja) | 2005-02-28 | 2012-05-30 | 株式会社抗体研究所 | 抗ＩｇＳＦ４抗体及びその利用 |
| CN103751780A (zh) | 2005-03-02 | 2014-04-30 | 比奥根艾迪克Ma公司 | 用于治疗th2介导的疾病的kim-1抗体 |
| WO2006099141A2 (en) | 2005-03-10 | 2006-09-21 | Morphotek, Inc. | Anti-mesothelin antibodies |
| JP2008532559A (ja) | 2005-03-19 | 2008-08-21 | メディカル リサーチ カウンシル | ウイルス感染の治療及び予防又は治療及び予防の改善 |
| ES2657443T3 (es) | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
| WO2006105448A2 (en) | 2005-03-30 | 2006-10-05 | Minerva Biotechnologies Corporation | Proliferation of muc1 expressing cells |
| DK1875244T3 (en) | 2005-03-30 | 2019-04-29 | Minerva Biotechnologies Corp | Proliferation of MUC1-Expressing Cells |
| TWI362940B (en) | 2005-03-31 | 2012-05-01 | Gen Hospital Corp | A use of agonist and/or antagonist of hgf/hgfr activity |
| CN101351710B (zh) | 2005-04-04 | 2013-06-05 | 生物基因Idecma公司 | 评价对治疗性蛋白质的免疫应答的方法和产品 |
| CA2607455A1 (en) | 2005-04-22 | 2006-11-02 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in endosialin-positive cells |
| JP2009521206A (ja) | 2005-04-22 | 2009-06-04 | モルフォテック、インク． | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
| US20090041783A1 (en) | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
| US8034902B2 (en) | 2005-05-04 | 2011-10-11 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against CD55 and CD59 and uses thereof |
| SI1879573T1 (sl) | 2005-05-10 | 2013-04-30 | Incyte Corporation Experimental Station | Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te |
| AU2006247188A1 (en) | 2005-05-18 | 2006-11-23 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against chlamydia infection |
| EP1888637A2 (en) | 2005-05-19 | 2008-02-20 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| AU2006249835B2 (en) | 2005-05-26 | 2011-09-08 | Musc Foundation For Research Development | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
| LT2460831T (lt) | 2005-05-27 | 2016-12-12 | Biogen Ma Inc. | Tweak rišantys antikūnai |
| US8354106B2 (en) | 2005-06-16 | 2013-01-15 | The Feinstein Institute For Medical Research | Antibodies against HMGB1 and fragments thereof |
| EP1907001B1 (en) | 2005-06-17 | 2015-07-15 | Merck Sharp & Dohme Corp. | Ilt3 binding molecules and uses therefor |
| PT2163562E (pt) * | 2005-06-21 | 2013-12-19 | Xoma Us Llc | Anticorpos de ligação a il 1 beta e respectivos fragmentos |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| CA2616189C (en) | 2005-07-22 | 2019-03-26 | Progenics Pharmaceuticals, Inc. | Methods for reducing viral load in hiv-1-infected patients |
| FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| US8652469B2 (en) | 2005-07-28 | 2014-02-18 | Novartis Ag | M-CSF-specific monoclonal antibody and uses thereof |
| WO2007030560A2 (en) | 2005-09-08 | 2007-03-15 | Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine | Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents |
| JP2009509970A (ja) | 2005-09-22 | 2009-03-12 | プロサイ インコーポレイテッド | 酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法 |
| JPWO2007049770A1 (ja) | 2005-10-28 | 2009-04-30 | 明治製菓株式会社 | 緑膿菌の外膜タンパク質ｐａ５１５８ |
| EP1948680A4 (en) | 2005-10-28 | 2010-01-13 | Univ California | METHOD AND COMPOUNDS FOR DETECTING AND ISOLATING LYMPHOMA CELLS |
| CA2626804A1 (en) | 2005-11-01 | 2007-08-09 | Abbott Biotechnology Ltd. | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
| JP2009516513A (ja) | 2005-11-21 | 2009-04-23 | ラボラトワール セローノ ソシエテ アノニム | ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用 |
| KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| ES2396440T3 (es) | 2006-01-18 | 2013-02-21 | The General Hospital Corporation | Métodos de aumentar la función linfática |
| WO2007096396A2 (en) | 2006-02-22 | 2007-08-30 | University Of Zurich | Methods for treating autoimmune or demyelinating diseases |
| JP2009534297A (ja) | 2006-03-10 | 2009-09-24 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７ａおよびｉｌ−１７ｆの両方に結合する抗体ならびにその使用方法 |
| EP2006379B1 (en) | 2006-03-23 | 2016-08-31 | Tohoku University | High functional bispecific antibody |
| CA2645904A1 (en) | 2006-03-30 | 2007-10-11 | Meiji Seika Kaisha, Ltd. | Pseudomonas aeruginosa outer membrane protein pa0427 |
| KR20140071452A (ko) | 2006-04-05 | 2014-06-11 | 애브비 바이오테크놀로지 리미티드 | 항체 정제 |
| US9624295B2 (en) | 2006-04-10 | 2017-04-18 | Abbvie Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| CA2564435A1 (en) | 2006-04-10 | 2007-10-10 | Abbott Biotechnology Ltd. | Methods for monitoring and treating intestinal disorders |
| EP2666479A3 (en) | 2006-04-10 | 2014-03-26 | Abbott Biotechnology Ltd | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| BRPI0712607A8 (pt) | 2006-05-25 | 2019-06-04 | Biogen Idec Inc | métodos de tratamento de acidente vascular cerebral |
| ATE553130T1 (de) | 2006-05-31 | 2012-04-15 | Astellas Pharma Inc | Humanisierter anti-human-osteopontin-antikörper |
| CA2653628C (en) | 2006-06-01 | 2015-07-14 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
| EP2046384A4 (en) | 2006-06-15 | 2009-12-02 | Fibron Ltd | ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME |
| AU2007345745C1 (en) | 2006-06-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
| MX2008016335A (es) | 2006-06-30 | 2009-01-21 | Abbott Biotech Ltd | Dispositivo automatico de inyeccion. |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| US8529911B2 (en) | 2006-07-07 | 2013-09-10 | Intercell Austria Ag | Small Streptococcus pyogenes antigens and their use |
| EP2078732B1 (en) | 2006-07-10 | 2015-09-16 | Fujita Health University | Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry |
| KR20090027241A (ko) | 2006-07-10 | 2009-03-16 | 바이오겐 아이덱 엠에이 인코포레이티드 | Ｓｍａｄ４-결핍 암의 성장을 억제하기 위한 조성물 및 방법 |
| WO2008019326A2 (en) | 2006-08-04 | 2008-02-14 | Novartis Ag | Ephb3-specific antibody and uses thereof |
| CA2660572C (en) | 2006-08-11 | 2014-07-22 | University Of Medicine And Dentistry Of New Jersey | Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof |
| ES2444065T3 (es) | 2006-08-18 | 2014-02-24 | Novartis Ag | Anticuerpo específico para PRLR y usos del mismo |
| EP2500415A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| NZ575328A (en) | 2006-09-13 | 2012-06-29 | Abbott Lab | Cell culture improvements |
| US20100297103A1 (en) | 2006-09-14 | 2010-11-25 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
| FR2906533B1 (fr) | 2006-09-28 | 2013-02-22 | Pf Medicament | Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations |
| WO2008052796A1 (en) | 2006-11-03 | 2008-05-08 | U3 Pharma Gmbh | Fgfr4 antibodies |
| CN103073641B (zh) | 2006-11-10 | 2015-01-21 | 株式会社立富泰克 | 在体内具有抗肿瘤活性的抗人Dlk-1抗体 |
| WO2008058736A1 (en) | 2006-11-17 | 2008-05-22 | Novartis Ag | Lingo binding molecules and pharmaceutical use thereof |
| EP1923069A1 (en) | 2006-11-20 | 2008-05-21 | Intercell AG | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
| US8288110B2 (en) | 2006-12-04 | 2012-10-16 | Perkinelmer Health Sciences, Inc. | Biomarkers for detecting cancer |
| CN101687032A (zh) | 2006-12-07 | 2010-03-31 | 诺瓦提斯公司 | 抗ephb3的拮抗剂抗体 |
| US8680252B2 (en) | 2006-12-10 | 2014-03-25 | Dyadic International (Usa), Inc. | Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi |
| US8440185B2 (en) | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
| AU2007339762B2 (en) | 2006-12-27 | 2011-03-31 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
| US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
| ES2533566T3 (es) | 2006-12-29 | 2015-04-13 | The Regents Of The University Of Colorado, A Body Corporate | Diana diagnóstica y terapéutica para enfermedades autoinmunitarias y sus usos |
| DK2426143T3 (en) | 2007-01-05 | 2017-09-11 | Univ Zuerich | Process for providing disease-specific binding molecules and targets |
| EP2269625A3 (en) | 2007-01-12 | 2012-08-08 | Intercell AG | Protective proteins of S. agalactiae, combinations thereof and methods of using the same |
| WO2008098139A2 (en) | 2007-02-07 | 2008-08-14 | The Regents Of The University Of Colorado | Axl tyrosine kinase inhibitors and methods of making and using the same |
| EP2130044B1 (en) | 2007-02-16 | 2016-10-26 | Genzyme Corporation | Method of identifying risk for thyroid disorder |
| PT2118300E (pt) | 2007-02-23 | 2015-09-22 | Univ California | Prevenção e tratamento da doença sinucleinopática e amiloidogénica |
| CA2678963C (en) | 2007-02-23 | 2018-05-01 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| CN101663047B (zh) | 2007-02-23 | 2014-07-09 | 纽约哥伦比亚大学理事会 | 通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径来治疗免疫疾病的方法 |
| MX2009009926A (es) | 2007-03-13 | 2010-03-15 | Univ Zuerich | Anticuerpo tumor-especifico humano monoclonal. |
| MX2009010120A (es) | 2007-03-22 | 2009-10-19 | Ucb Pharma Sa | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. |
| PT2620451T (pt) | 2007-04-05 | 2016-12-20 | Morphotek Inc | Métodos para inibir a ligação da endosialina a ligandos |
| WO2008134659A2 (en) | 2007-04-27 | 2008-11-06 | Zymogenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
| WO2008135446A2 (en) | 2007-05-02 | 2008-11-13 | Intercell Ag | Klebsiella antigens |
| EP2160403B1 (en) | 2007-05-11 | 2018-08-08 | Genzyme Corporation | Methods of producing a secreted protein |
| US7709215B2 (en) | 2007-06-01 | 2010-05-04 | Cytonics Corporation | Method for diagnosing and treating acute joint injury |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| EP2171451A4 (en) | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| PT2170390T (pt) | 2007-06-14 | 2019-02-12 | Biogen Ma Inc | Formulações com anticorpo natalizumab |
| JP2010530229A (ja) | 2007-06-18 | 2010-09-09 | インターセル アーゲー | クラミジア属の抗原 |
| WO2009000006A1 (en) | 2007-06-26 | 2008-12-31 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Display of binding agents |
| CA2690888C (en) | 2007-06-27 | 2016-02-09 | Asubio Pharma Co., Ltd. | Cancer therapeutic composition comprising antibody against peptide encoded by exon-17 site of periostin |
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| EP3124046B1 (en) | 2007-07-12 | 2019-12-25 | GITR, Inc. | Combination therapies employing gitr binding molecules |
| EP2514762B1 (en) | 2007-07-13 | 2015-04-08 | The Johns Hopkins University | B7-DC variants |
| WO2009017833A2 (en) | 2007-08-02 | 2009-02-05 | Arresto Biosciences | Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis |
| ES2618316T3 (es) | 2007-08-30 | 2017-06-21 | Daiichi Sankyo Company, Limited | Anticuerpo anti EPHA2 |
| CN101848999A (zh) * | 2007-09-06 | 2010-09-29 | 国立大学法人大阪大学 | 抗-cd20单克隆抗体 |
| EP2197893B1 (en) | 2007-09-07 | 2013-07-24 | Dyadic International, Inc. | Novel fungal enzymes |
| EP2185592B1 (en) | 2007-09-13 | 2013-01-23 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| WO2009036209A2 (en) | 2007-09-14 | 2009-03-19 | Amgen Inc. | Homogeneous antibody populations |
| AU2008311367B2 (en) | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| NZ583397A (en) | 2007-10-11 | 2012-03-30 | Daiichi Sankyo Co Ltd | ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15 |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| CN101965365A (zh) | 2007-10-19 | 2011-02-02 | 伊缪纳斯制药株式会社 | 能够特异性结合Aβ寡聚体的抗体及其应用 |
| EP2217720A4 (en) | 2007-11-01 | 2010-12-08 | Univ Iowa Res Found | RNA LOCUS ANALYSIS TO ASSESS THE STUNNING FOR AMD AND MPGNII |
| US8163285B2 (en) | 2007-11-02 | 2012-04-24 | Novartis Ag | Nogo-A binding molecules and pharmaceutical use thereof |
| JP2011514881A (ja) | 2007-11-09 | 2011-05-12 | ザ ソルク インスティテュート フォー バイオロジカル スタディーズ | 免疫増強剤としてのｔａｍ受容体阻害剤の使用および免疫抑制剤としてのｔａｍ活性化剤の使用 |
| CA2705164A1 (en) | 2007-11-12 | 2009-05-22 | U3 Pharma Gmbh | Axl antibodies |
| CN102131920B (zh) | 2007-11-28 | 2013-11-06 | 宾夕法尼亚大学托管会 | 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用 |
| KR101662574B1 (ko) | 2007-11-28 | 2016-10-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38 |
| EP2808345A3 (en) | 2007-12-05 | 2015-03-11 | Massachusetts Institute of Technology | Aglycosylated immunoglobulin mutants |
| EP2231181B1 (en) | 2007-12-17 | 2016-02-17 | Marfl AB | New vaccine for the treatment of mycobacterium related disorders |
| WO2009081955A1 (ja) | 2007-12-25 | 2009-07-02 | Meiji Seika Kaisha, Ltd. | 緑膿菌のiii型分泌装置構成タンパク質pa1698 |
| AU2008345022B2 (en) | 2007-12-28 | 2014-11-06 | Prothena Biosciences Limited | Treatment and prophylaxis of amyloidosis |
| JP5511684B2 (ja) | 2008-01-11 | 2014-06-04 | アドヘロン セラピューティクス，インコーポレイテッド | 炎症性関節障害を治療するためのカドヘリン−１１ｅｃｌドメインアンタゴニスト |
| AU2009203350B2 (en) | 2008-01-11 | 2014-03-13 | Gene Techno Science Co., Ltd. | Humanized anti-alpha9 integrin antibodies and the uses thereof |
| RU2503720C2 (ru) | 2008-01-11 | 2014-01-10 | Астеллас Фарма Инк. | УЛУЧШЕННОЕ ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К ЧЕЛОВЕЧЕСКОМУ α9-ИНТЕГРИНУ |
| CN102936287B (zh) | 2008-02-08 | 2015-09-09 | 伊缪纳斯制药株式会社 | 能够特异性结合Aβ寡聚体的抗体及其应用 |
| CA2716928C (en) | 2008-03-04 | 2018-04-10 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof |
| RU2540018C2 (ru) | 2008-03-13 | 2015-01-27 | Биотест Аг | Средство для лечения заболевания |
| CN102027016A (zh) | 2008-03-13 | 2011-04-20 | 生物测试股份公司 | 一种治疗疾病的试剂 |
| KR20100135257A (ko) | 2008-03-13 | 2010-12-24 | 바이오테스트 아게 | 질병 치료제 |
| WO2009116670A1 (ja) | 2008-03-17 | 2009-09-24 | 株式会社リブテック | in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体 |
| US8241643B2 (en) | 2008-03-17 | 2012-08-14 | Intercell Ag | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
| WO2009115531A2 (en) | 2008-03-17 | 2009-09-24 | Universitätsklinikum Münster | Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions |
| EP2260863A1 (en) | 2008-03-27 | 2010-12-15 | Takara Bio, Inc. | Prophylactic/therapeutic agent for infectious disease |
| MY159553A (en) | 2008-04-11 | 2017-01-13 | Seattle Genetics Inc | Detection and treatment of pancreatic, ovarian and other cancers |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| CN102076865B (zh) | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物 |
| US9096681B2 (en) | 2008-06-02 | 2015-08-04 | Dana-Farber Cancer Institute, Inc. | XBP1, CD138, and CS1 peptides |
| CA2728473A1 (en) | 2008-06-20 | 2009-12-23 | National University Corporation Okayama University | Antibody against oxidized ldl/.beta.2gpi complex and use of the same |
| CA2728004C (en) | 2008-06-25 | 2022-05-24 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanization of rabbit antibodies using a universal antibody framework |
| ES2677003T3 (es) | 2008-06-25 | 2018-07-27 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos |
| PT3444274T (pt) | 2008-06-25 | 2021-03-17 | Novartis Ag | Anticorpos que inibem tnf estáveis e solúveis |
| NO2824100T3 (no) | 2008-07-08 | 2018-07-21 | ||
| US8993728B2 (en) | 2008-07-16 | 2015-03-31 | Medical And Biological Laboratories Co., Ltd. | Anti-human CLCP1 antibody and use thereof |
| US8961991B2 (en) | 2009-03-10 | 2015-02-24 | Baylor Research Institute | Anti-CD40 targeted fusion proteins |
| EP2322220B1 (en) | 2008-08-01 | 2014-01-01 | Axis, Inc. | Therapeutic agent or preventive agent for osteoarthritis |
| US8795981B2 (en) | 2008-08-08 | 2014-08-05 | Molecular Devices, Llc | Cell detection |
| US8417011B2 (en) | 2008-09-18 | 2013-04-09 | Molecular Devices (New Milton) Ltd. | Colony detection |
| EP2172485A1 (en) | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
| EP2679238A1 (en) | 2008-10-02 | 2014-01-01 | Celtaxsys, INC. | Methods of modulating the negative chemotaxis of immune cells |
| KR20170110740A (ko) | 2008-10-09 | 2017-10-11 | 미네르바 바이오테크놀로지 코포레이션 | 세포내에서 다능성을 유도하기 위한 방법 |
| WO2010051105A1 (en) | 2008-10-29 | 2010-05-06 | China Synthetic Rubber Corporation | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| WO2010051367A1 (en) | 2008-10-31 | 2010-05-06 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof |
| US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
| AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| ES2544569T3 (es) | 2008-12-19 | 2015-09-01 | Biogen International Neuroscience Gmbh | Autoanticuerpos humanos anti alfa-sinucleina |
| US8313915B2 (en) | 2009-01-21 | 2012-11-20 | Gundersen Lutheran Medical Foundation, Inc. | Early detection of canine lyme disease by specific peptides and antibodies |
| WO2010085590A1 (en) | 2009-01-23 | 2010-07-29 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria |
| US20130243779A1 (en) | 2009-02-05 | 2013-09-19 | Intercell Ag | Peptides protective against e. faecalis, methods and uses relating thereto |
| US8617574B2 (en) | 2009-02-13 | 2013-12-31 | Valneva Austria Gmbh | Nontypable Haemophilus influenzae antigens |
| US20110306069A1 (en) | 2009-02-19 | 2011-12-15 | Qingyu Wu | Corin As A Marker For Heart Failure |
| CN103415534A (zh) | 2009-03-10 | 2013-11-27 | 贝勒研究院 | 靶向抗原呈递细胞的癌症疫苗 |
| CA3032548C (en) | 2009-03-10 | 2023-05-09 | Baylor Research Institute | Anti-cd40 antibodies and uses thereof |
| EP2412808B1 (en) | 2009-03-25 | 2016-09-07 | Tohoku University | Lh-type bispecific antibody |
| CA2750836C (en) | 2009-04-09 | 2018-05-01 | Daiichi Sankyo Company, Limited | Anti-siglec-15 antibody |
| CA2758322C (en) | 2009-04-10 | 2019-04-02 | Tufts Medical Center, Inc. | Par-1 activation by metalloproteinase-1 (mmp-1) |
| DK2419447T3 (en) | 2009-04-17 | 2017-09-25 | Immunas Pharma Inc | ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF |
| JP5677411B2 (ja) | 2009-04-29 | 2015-02-25 | アッヴィ バイオテクノロジー リミテッド | 自動注入機器 |
| EP2246364A1 (en) | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
| EP2270053A1 (en) | 2009-05-11 | 2011-01-05 | U3 Pharma GmbH | Humanized AXL antibodies |
| CN102575232B (zh) | 2009-05-29 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿腺病毒41及其应用 |
| EP2260864A1 (en) | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutic applications |
| TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| WO2011011775A1 (en) | 2009-07-24 | 2011-01-27 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with avb5 integrin |
| JP5426026B2 (ja) | 2009-07-28 | 2014-02-26 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 非侵襲性インビボ光学イメージング方法 |
| US20120164659A1 (en) | 2009-08-05 | 2012-06-28 | Nexigen Gmbh | Human hcv-interacting proteins and methods of use |
| WO2011024114A1 (en) | 2009-08-25 | 2011-03-03 | Ecole Polytechnique Federale De Lausanne (Epfl) | Targeting extracellular matrix molecules for the treatment of cancer |
| TWI412375B (zh) | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗ｃｄｃｐ１抗體 |
| US9005616B2 (en) | 2009-08-31 | 2015-04-14 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
| WO2011032119A1 (en) | 2009-09-14 | 2011-03-17 | The Regents Of The University Of Colorado | Modulation of yeast-based immunotherapy products and responses |
| EP2305285A1 (en) | 2009-09-29 | 2011-04-06 | Julius-Maximilians-Universität Würzburg | Means and methods for treating ischemic conditions |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| EP2308897A1 (en) | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer |
| WO2011044553A1 (en) | 2009-10-11 | 2011-04-14 | Biogen Idec Ma Inc. | Anti-vla-4 related assays |
| WO2011062112A1 (ja) | 2009-11-18 | 2011-05-26 | 国立大学法人東北大学 | ヒト型化抗ｅｇｆｒ抗体可変領域の高機能性変異体 |
| EP2332929A1 (en) | 2009-11-25 | 2011-06-15 | ArisGen SA | Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions |
| GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| US9872905B2 (en) | 2009-12-01 | 2018-01-23 | President And Fellows Of Harvard College | Modulation of NK cell antigen specific effector activity by modulation of CXCR6 (CD186) |
| US20110150891A1 (en) | 2009-12-16 | 2011-06-23 | Philip Bosch | Methods of Treating Interstitial Cystitis |
| US9221759B2 (en) | 2010-01-13 | 2015-12-29 | Rutgers, The State University Of New Jersey | Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency |
| CA2787783A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
| WO2011091181A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| KR20120115383A (ko) | 2010-01-29 | 2012-10-17 | 가부시키가이샤 아크시스 | 변형성 관절증 치료 또는 예방용 의약 조성물 및 이의 제조 방법 |
| JP2012246222A (ja) | 2010-01-29 | 2012-12-13 | Axis Inc | 変形性関節症治療剤または予防剤を製造するための使用 |
| EP2529751A4 (en) | 2010-01-29 | 2013-07-31 | Axis Inc | INJECTABLE SOLUTION WITH A MEANS FOR THE TREATMENT OF OSTEOARTHRITIS |
| US20120014956A1 (en) | 2010-02-02 | 2012-01-19 | Hartmut Kupper | Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor |
| WO2011097627A1 (en) | 2010-02-08 | 2011-08-11 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 161p2f10b proteins |
| JP2013520173A (ja) | 2010-02-18 | 2013-06-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インテグリンαｖβ８中和抗体 |
| WO2011109398A2 (en) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| AU2011223456A1 (en) | 2010-03-03 | 2012-10-18 | The University Of British Columbia | Oligomer-specific amyloid beta epitope and antibodies |
| AU2011231558B2 (en) | 2010-03-26 | 2016-08-11 | Westfaelische Wilhelms-Universitaet Muenster | Substitute therapy for glucocorticoids |
| EP2371863A1 (en) | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
| EP3434694B1 (en) | 2010-04-09 | 2020-12-30 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
| PT3202789T (pt) | 2010-04-16 | 2020-06-16 | Biogen Ma Inc | Anticorpos anti-vla-4 |
| KR101970467B1 (ko) | 2010-04-21 | 2019-04-19 | 애브비 바이오테크놀로지 리미티드 | 치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스 |
| CN102939538A (zh) | 2010-05-07 | 2013-02-20 | 霍夫曼-拉罗奇有限公司 | 用于离体检测细胞的诊断方法 |
| JP5859434B2 (ja) | 2010-05-17 | 2016-02-10 | 株式会社カイオム・バイオサイエンス | ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＴＲＯＰ−２抗体 |
| WO2011146727A1 (en) | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of treating interstitial cystitis |
| EP2592161B1 (en) | 2010-07-08 | 2016-02-03 | Honda Motor Co., Ltd. | High frequency heating coil |
| DK2593475T3 (en) | 2010-07-14 | 2016-05-30 | Merck Sharp & Dohme | Anti-ADDL monoclonal antibody and uses thereof |
| JP5886283B2 (ja) | 2010-07-15 | 2016-03-16 | アドヘロン セラピューティクス，インコーポレイテッド | カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
| DK2598526T3 (en) | 2010-07-29 | 2018-11-19 | Eleven Biotherapeutics Inc | CHEMICAL IL-1 RECEPTOR TYPE-I AGONISTS AND ANTAGONISTS |
| WO2012016173A2 (en) | 2010-07-30 | 2012-02-02 | Ac Immune S.A. | Safe and functional humanized antibodies |
| JP2012034668A (ja) | 2010-08-12 | 2012-02-23 | Tohoku Univ | ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用 |
| WO2012027494A1 (en) | 2010-08-24 | 2012-03-01 | Regents Of The University Of Minnesota | Bispecific targeting reagents |
| WO2012025636A1 (en) | 2010-08-27 | 2012-03-01 | University Of Zurich | Method for target and drug validation in inflammatory and/or cardiovascular diseases |
| WO2012025633A1 (en) | 2010-08-27 | 2012-03-01 | University Of Zurich | A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases |
| WO2012028697A1 (en) | 2010-09-01 | 2012-03-08 | Eth Zürich, Institute Of Molecular Biology And Biophysics | Affinity purification system based on donor strand complementation |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| JP5843170B2 (ja) | 2010-09-30 | 2016-01-13 | 国立研究開発法人理化学研究所 | グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤 |
| US8497138B2 (en) | 2010-09-30 | 2013-07-30 | Genetix Limited | Method for cell selection |
| PL2627672T3 (pl) | 2010-10-11 | 2018-11-30 | Biogen International Neuroscience Gmbh | Ludzkie przeciwciała anty-tau |
| BR112013009083B1 (pt) | 2010-10-13 | 2021-08-10 | Janssen Biotech, Inc. | Anticorpos humanos para oncostatina m, seu processo de fabricação, fragmento de ligação a antígeno, composição farmacêutica, polinucleotídeo isolado, célula hospedeira recombinante estavelmente transformada ou transfectada |
| CA2813796C (en) | 2010-10-18 | 2019-01-15 | Mediapharma S.R.L. | Erbb3 binding antibody |
| TWI545134B (zh) | 2010-10-22 | 2016-08-11 | 西雅圖遺傳學公司 | 以奧裡斯他汀（ＡＵＲＩＳＴＡＴＩＮ）為主之抗體藥物結合物及ＰＩ３Ｋ－ＡＫＴ ｍＴＯＲ路徑抑制劑間的協同功效 |
| UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| EP3722808A1 (en) | 2010-10-25 | 2020-10-14 | Biogen MA Inc. | Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels |
| CA2814908A1 (en) | 2010-10-27 | 2012-05-03 | Pierre Fabre Medicament | Antibodies for the treatment of hiv |
| JP5918143B2 (ja) | 2010-10-29 | 2016-05-18 | 第一三共株式会社 | 新規抗ｄｒ５抗体 |
| US9072766B2 (en) | 2010-11-18 | 2015-07-07 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT) |
| PE20180249A1 (es) | 2010-11-19 | 2018-02-02 | Eisai Randd Man Co Ltd | Anticuerpos neutralizadores anti-ccl20 |
| AU2011332025B2 (en) | 2010-11-23 | 2015-06-25 | The Trustees Of The University Of Pennsylvania | Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof |
| US9283271B2 (en) | 2010-12-17 | 2016-03-15 | Neurimmune Holding Ag | Human anti-SOD1 antibodies |
| JP5883396B2 (ja) | 2010-12-27 | 2016-03-15 | 国立大学法人名古屋大学 | 受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法 |
| CN103347898B (zh) | 2011-01-10 | 2017-12-05 | Ct大西洋有限公司 | 包括与肿瘤相关抗原结合抗体的联合治疗 |
| ES2865068T3 (es) | 2011-01-14 | 2021-10-14 | Univ California | Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos |
| CN106075664B (zh) | 2011-01-24 | 2019-07-02 | 艾伯维生物技术有限公司 | 具有模制抓握面的自动注射装置 |
| WO2012104824A1 (en) | 2011-02-04 | 2012-08-09 | Ecole polytechnique fédérale de Lausanne (EPFL) | Therapeutic antibodies targeting app-c99 |
| WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
| WO2012110843A1 (en) | 2011-02-18 | 2012-08-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis |
| WO2012113775A1 (en) | 2011-02-21 | 2012-08-30 | University Of Zurich | Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders |
| JP6385060B2 (ja) | 2011-03-07 | 2018-09-05 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 治療的に活性な抗体のインビボにおける選択 |
| EP2683290B1 (en) | 2011-03-07 | 2018-11-07 | F.Hoffmann-La Roche Ag | Methods for in vivo testing of therapeutic antibodies |
| EP2684045B2 (en) | 2011-03-09 | 2023-03-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods to characterize patients suffering from hemolysis |
| WO2012125680A1 (en) | 2011-03-16 | 2012-09-20 | Novartis Ag | Methods of treating vasculitis using an il-17 binding molecule |
| ES2588730T3 (es) | 2011-03-17 | 2016-11-04 | Miltenyi Biotec Gmbh | Preparados celulares agotados en lo que respecta a TCRalfa/beta |
| EP2688592A4 (en) | 2011-03-25 | 2015-07-22 | Baylor Res Inst | COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST HEPATITIS C VIRUS |
| TW201249867A (en) | 2011-04-01 | 2012-12-16 | Astellas Pharma Inc | Novel anti-human il-23 receptor antibody |
| AU2012245211B2 (en) | 2011-04-21 | 2016-03-10 | Abbvie Inc. | Wearable automatic injection device |
| PL2703486T3 (pl) | 2011-04-25 | 2018-07-31 | Daiichi Sankyo Company, Limited | Przeciwciało anty-b7-h3 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| EA032625B1 (ru) | 2011-05-02 | 2019-06-28 | Милленниум Фармасьютикалз, Инк. | КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| EP2707711A1 (en) | 2011-05-09 | 2014-03-19 | The Cleveland Clinic Foundation | Serum s100b and uses thereof |
| WO2012163848A1 (en) | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of crohn's disease |
| EP2530088A1 (en) | 2011-05-30 | 2012-12-05 | Klinikum rechts der Isar der Technischen Universität München | Means and methods for diagnosing and treating multiple sclerosis |
| US20140093514A1 (en) | 2011-06-03 | 2014-04-03 | University Of Zurich | Magea3 binding antibodies |
| US20140186363A1 (en) | 2011-06-03 | 2014-07-03 | University Of Zurich | Magea3 binding antibodies |
| US20140314744A1 (en) | 2011-06-06 | 2014-10-23 | Neotope Biosciences Limited | Mcam antagonists and methods of treatment |
| WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
| US20140120555A1 (en) | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
| DK2723379T3 (en) | 2011-06-23 | 2018-10-15 | Biogen Int Neuroscience Gmbh | ANTI-ALPHA SYNUCLEIN BINDING MOLECULES |
| DE202011103324U1 (de) | 2011-07-12 | 2012-01-02 | Nekonal S.A.R.L. | Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten |
| GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| EP2737083A1 (en) | 2011-07-27 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Scientifique) | Methods for diagnosing and treating myhre syndrome |
| HUE036079T2 (hu) | 2011-08-11 | 2018-06-28 | Astellas Pharma Inc | Új anti-humán NGF antitest |
| US20140242085A1 (en) | 2011-08-12 | 2014-08-28 | Medical & Biological Laboratories Co., Ltd. | Methods and composition for testing, preventing, and treating aspergillus fumigatus infection |
| US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| SG10201703771WA (en) | 2011-09-19 | 2017-06-29 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
| GB2495115A (en) * | 2011-09-29 | 2013-04-03 | Oxford Plastic Sys Ltd | Base for supporting temporary fence panels or posts. |
| AR088048A1 (es) | 2011-10-04 | 2014-05-07 | Univ Columbia | Señuelos notch1 humanos |
| US20140248294A1 (en) | 2011-10-05 | 2014-09-04 | University Of Bremen | Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases |
| WO2013050441A1 (en) | 2011-10-05 | 2013-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| WO2013055911A1 (en) | 2011-10-14 | 2013-04-18 | Dana-Farber Cancer Institute, Inc. | Znf365/zfp365 biomarker predictive of anti-cancer response |
| JP6466170B2 (ja) | 2011-10-17 | 2019-02-06 | ミネルバ バイオテクノロジーズ コーポレーション | 幹細胞の増殖及び誘導用の培地 |
| WO2013057313A1 (en) | 2011-10-20 | 2013-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the detection and the treatment of cardiac remodeling |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| JP2015506911A (ja) | 2011-11-22 | 2015-03-05 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 気道過敏症を低減させるための方法および薬学的組成物 |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| ES2638649T3 (es) | 2011-11-28 | 2017-10-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Composición farmacéutica para su uso en el tratamiento de disfunciones asociadas al envejecimiento |
| EP2602621A1 (en) | 2011-12-08 | 2013-06-12 | Julius-Maximilians-Universität Würzburg | LASP-1, a novel urinary marker for transitional cell carcinoma detection |
| JP2015501654A (ja) * | 2011-12-13 | 2015-01-19 | ノルディック ナノベクター アーエス | 治療用キメラ型抗ｃｄ３７抗体ｈｈ１ |
| FR2984750B1 (fr) | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
| EP2794660A2 (en) | 2011-12-23 | 2014-10-29 | Phenoquest AG | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
| WO2013098420A1 (en) | 2011-12-28 | 2013-07-04 | Immunoqure Ag | Method of isolating human antibodies |
| JP2015509085A (ja) | 2012-01-01 | 2015-03-26 | キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． | 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子 |
| EP2812702B1 (en) | 2012-02-10 | 2019-04-17 | Seattle Genetics, Inc. | Diagnosis and management of CD30-expressing cancers |
| JP6345123B2 (ja) | 2012-02-16 | 2018-06-20 | サンタラス， インコーポレイテッド | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
| EP2817340B1 (en) | 2012-02-23 | 2020-12-09 | Daiichi Sankyo Europe GmbH | Her3 inhibitor for modulating radiosensitivity |
| ES2701064T3 (es) | 2012-02-28 | 2019-02-20 | Astellas Pharma Inc | Novedoso anticuerpo antirreceptor IL-23 humano |
| CA2867299C (en) | 2012-03-15 | 2019-08-27 | John Chen | Human anti-cd27 antibodies, methods, and uses |
| SI2828284T1 (sl) | 2012-03-20 | 2019-10-30 | Biogen Ma Inc | Virus JC nevtralizirajoča protitelesa |
| JPWO2013147212A1 (ja) | 2012-03-30 | 2015-12-14 | 第一三共株式会社 | 新規抗Ｓｉｇｌｅｃ−１５抗体 |
| CA2868959A1 (en) | 2012-03-30 | 2013-10-03 | Daiichi Sankyo Company, Limited | Cdr-modified anti-siglec-15 antibody |
| CN103382223B (zh) | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
| EP3492095A1 (en) | 2012-04-01 | 2019-06-05 | Technion Research & Development Foundation Limited | Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies |
| EP2834641A1 (en) | 2012-04-02 | 2015-02-11 | Gundersen Lutheran Health Systems, Inc. | Reagents, methods, and kits for the classification of cancer |
| SG10201608382QA (en) | 2012-04-09 | 2016-12-29 | Daiichi Sankyo Co Ltd | Anti-fgfr2 antibody |
| PL2841457T3 (pl) | 2012-04-27 | 2019-09-30 | Daiichi Sankyo Company, Limited | Przeciwciało anty-ROBO4 |
| US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
| US9416189B2 (en) | 2012-05-11 | 2016-08-16 | Microbial Chemistry Research Foundation | Anti-CXADR antibody |
| US9512223B2 (en) | 2012-05-15 | 2016-12-06 | Morphotek, Inc. | Methods for treatment of gastric cancer |
| CA2873509A1 (en) | 2012-05-18 | 2013-11-21 | The Trustees Of The University Of Pennsylvania | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof |
| JP2015520373A (ja) | 2012-05-22 | 2015-07-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 巣状分節性糸球体硬化症を診断及び処置するための方法 |
| EP3508497A1 (en) | 2012-05-24 | 2019-07-10 | Mountgate Group Limited | Compositions and methods related to prevention and treatment of rabies infection |
| US20150202286A1 (en) | 2012-07-13 | 2015-07-23 | The Children's Hospital of Philadelphai | Toxicity Management for Anti-Tumor Activity of CARs |
| US20150184155A1 (en) | 2012-07-18 | 2015-07-02 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for preventing and treating chronic kidney disease (ckd) |
| KR102165464B1 (ko) | 2012-07-19 | 2020-10-14 | 레드우드 바이오사이언스 인코포레이티드 | Cd22에 대해 특이적인 항체 및 이들의 사용 방법 |
| EP2881467B1 (en) | 2012-07-30 | 2018-10-31 | National University Corporation Nagoya University | Monoclonal antibody against human midkine |
| KR102312856B1 (ko) | 2012-08-24 | 2021-10-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
| TW201922795A (zh) | 2012-09-10 | 2019-06-16 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| JP6282591B2 (ja) | 2012-09-13 | 2018-02-21 | 中外製薬株式会社 | 遺伝子ノックイン非ヒト動物 |
| EP2711016A1 (en) | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
| LT2905335T (lt) | 2012-10-03 | 2018-04-10 | Chiome Bioscience Inc. | Antikūnas prieš žmogaus dlk-1, pasižymintis priešnavikiniu aktyvumu in vivo sąlygomis |
| ES2776029T3 (es) | 2012-10-08 | 2020-07-28 | St Jude Childrens Res Hospital | Terapias basadas en el control de la estabilidad y función de las células T reguladoras por medio de un eje neuropilina-1:semaforina |
| SG10201804788XA (en) | 2012-10-11 | 2018-07-30 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate |
| DE102012020496A1 (de) | 2012-10-18 | 2014-04-24 | Charité - Universitätsmedizin Berlin | Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1 |
| JP6272230B2 (ja) | 2012-10-19 | 2018-01-31 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート |
| US20150246118A1 (en) | 2012-10-26 | 2015-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis |
| JP6694712B2 (ja) | 2012-11-01 | 2020-05-20 | マックス−デルブルック−セントラム フアー モレキュラーレ メデジン | Ｃｄ２６９（ｂｃｍａ）に対する抗体 |
| KR102167228B1 (ko) | 2012-11-05 | 2020-10-19 | 피에르 파브르 메디카먼트 | 새로운 항원 결합 단백질들 및 암의 치료를 위한 어드레싱 산물로서 그들의 용도 |
| JP6445446B2 (ja) | 2012-11-08 | 2018-12-26 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 骨転移の治療のための方法及び医薬組成物 |
| AR093445A1 (es) | 2012-11-14 | 2015-06-10 | Regeneron Pharma | Metodos para tratar el cancer de ovario con antagonistas de dll4 |
| NZ708033A (en) | 2012-12-10 | 2020-03-27 | Biogen Ma Inc | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
| EP2931749B1 (fr) | 2012-12-17 | 2019-04-24 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
| WO2014100602A1 (en) | 2012-12-20 | 2014-06-26 | Hospital For Special Surgery | Treatment of egf-receptor dependent pathologies |
| ES2816700T3 (es) | 2012-12-21 | 2021-04-05 | Biogen Ma Inc | Anticuerpos anti-tau humanos |
| WO2014102399A1 (en) | 2012-12-31 | 2014-07-03 | Neurimmune Holding Ag | Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases |
| EP2752426A1 (en) | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
| BR112015018035A2 (pt) | 2013-01-28 | 2017-11-21 | Evec Inc | anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno |
| WO2014118317A1 (en) | 2013-02-01 | 2014-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and preventing metastasis in triple negative breast cancers |
| WO2014123227A1 (ja) | 2013-02-08 | 2014-08-14 | 株式会社医学生物学研究所 | ヒトｎｒｇ１タンパク質に対する抗体 |
| AU2013378628A1 (en) | 2013-02-15 | 2015-06-11 | Esbatech - A Novartis Company Llc | Acceptor framework for CDR grafting |
| JP2016506752A (ja) | 2013-02-20 | 2016-03-07 | エスバテック − ア ノバルティスカンパニー エルエルシー | Ｃｄｒグラフトのためのアクセプターフレームワーク |
| FR3004184B1 (fr) | 2013-02-26 | 2016-03-18 | Agronomique Inst Nat Rech | Anticorps anti-gluten desamide et utilisations. |
| EP2963059B1 (en) | 2013-02-28 | 2018-04-04 | National Cancer Center | Antibody against insoluble fibrin |
| JP6218088B2 (ja) | 2013-03-08 | 2017-11-01 | 国立大学法人大阪大学 | ペリオスチンのＥｘｏｎ−２１部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物 |
| WO2014160371A1 (en) | 2013-03-13 | 2014-10-02 | Eleven Biotherapeutics, Inc. | Chimeric cytokine formulations for ocular delivery |
| US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
| US10081673B2 (en) | 2013-03-14 | 2018-09-25 | Ffe Therapeutics Llc | Compositions and methods for treating angiogenesis-related disorders |
| US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CA2903546A1 (en) | 2013-03-15 | 2014-09-25 | Biogen Ma Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
| US10035860B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
| WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| HUE040234T2 (hu) | 2013-03-18 | 2019-02-28 | Biocerox Prod Bv | Humanizált anti-CD134 (OX40) antitestek és felhasználásaik |
| EP2981554B1 (en) | 2013-04-01 | 2020-07-29 | The Regents of The University of California | Methods and compositions for treating and preventing disease associated with avb8 integrin |
| WO2014174596A1 (ja) | 2013-04-23 | 2014-10-30 | 株式会社医学生物学研究所 | ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体 |
| US9717648B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| CN104140974B (zh) | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| EP3011334A1 (en) | 2013-06-20 | 2016-04-27 | The Trustees Of The University Of Pennsylvania | Methods for diagnosing pancreatic cancer |
| US10112995B2 (en) | 2013-07-03 | 2018-10-30 | Immunoqure Ag | Human anti-IFN-α antibodies |
| US20160176943A1 (en) | 2013-07-05 | 2016-06-23 | Inserm (Insititut National De La Sante Et De La Recherche Medicale) | Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof |
| WO2015003114A1 (en) | 2013-07-05 | 2015-01-08 | University Of Washington Through Its Center For Commercialization | Soluble mic neutralizing monoclonal antibody for treating cancer |
| TR201906969T4 (tr) | 2013-08-09 | 2019-06-21 | Astellas Pharma Inc | Yeni anti-insan tslp reseptör antikoru. |
| US20160216262A1 (en) | 2013-09-12 | 2016-07-28 | Institut National De La Sante Et De La Recherche Medicale | Method for In Vitro Quantifying Allo-Antibodies, Auto-Antibodies and/or Therapeutic Antibodies |
| CA2924020A1 (en) | 2013-09-20 | 2015-03-26 | Westfaelische Wilhelms-Universitaet Muenster | Cell-penetrating bacterial e3-ubiqitin-ligases for use in immunotherapy |
| EP3049438B1 (en) | 2013-09-24 | 2018-07-25 | The Feinstein Institute for Medical Research | Peptides inhibiting cold-inducible rna binding protein activity |
| EP3049085B9 (en) | 2013-09-26 | 2021-08-18 | Beth Israel Deaconess Medical Center, Inc. | Sgk1 inhibitors in the treatment of long qt syndrome |
| RU2016116949A (ru) | 2013-09-30 | 2017-11-10 | Дайити Санкио Компани, Лимитед | Анти-лпс о11-антитело |
| US10259875B2 (en) | 2013-10-01 | 2019-04-16 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of BIM |
| JP6509735B2 (ja) | 2013-10-08 | 2019-05-08 | 第一三共株式会社 | 抗ｆｇｆｒ２抗体と他剤の組合せ |
| RS62373B1 (sr) | 2013-11-06 | 2021-10-29 | Janssen Biotech Inc | Anti-ccl17 antitela |
| JPWO2015068781A1 (ja) | 2013-11-06 | 2017-03-09 | 国立大学法人大阪大学 | インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体 |
| WO2015071701A1 (en) | 2013-11-15 | 2015-05-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of pancreatic cancers |
| WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
| MX2016008520A (es) | 2013-12-24 | 2016-11-30 | Astellas Pharma Inc | Anticuerpo bdca-2 antihumano novedoso. |
| RU2705367C2 (ru) | 2013-12-25 | 2019-11-07 | Дайити Санкио Компани, Лимитед | Конъюгат анти-trop2 антитело-лекарственное средство |
| AU2015205327B2 (en) | 2014-01-09 | 2019-02-14 | Hadasit Medical Research Services And Development Ltd. | Improved cell compositions and methods for cancer therapy |
| EP3094652B1 (en) | 2014-01-13 | 2021-09-29 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
| CN104774264B (zh) | 2014-01-15 | 2018-09-14 | 上海易乐生物技术有限公司 | 抗人proBDNF单克隆抗体及其在疼痛中的作用 |
| KR102275925B1 (ko) | 2014-01-31 | 2021-07-12 | 다이이찌 산쿄 가부시키가이샤 | 항-her2 항체-약물 접합체 |
| WO2015124570A1 (en) | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of influenza a virus infection |
| EP3108255B1 (en) | 2014-02-18 | 2020-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway |
| EP2915543B1 (en) | 2014-03-04 | 2018-05-09 | Albert-Ludwigs-Universität Freiburg | Polypeptides derived from Enterococcus and their use for vaccination and the generation of therapeutic antibodies |
| WO2015140351A1 (en) | 2014-03-21 | 2015-09-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for enhancing myelination |
| WO2015145449A2 (en) | 2014-03-27 | 2015-10-01 | Yeda Research And Development Co. Ltd. | T-cell receptor cdr3 peptides and antibodies |
| RS61711B1 (sr) | 2014-04-10 | 2021-05-31 | Daiichi Sankyo Co Ltd | Anti-her3 antitelo-lek konjugat |
| CA2944903A1 (en) | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| JP6258523B2 (ja) | 2014-04-25 | 2018-01-10 | ピエール、ファーブル、メディカマン | Ｉｇｆ−１ｒ抗体−薬物複合体および癌の処置のためのその使用 |
| CN106470708B (zh) | 2014-04-25 | 2019-12-31 | 皮埃尔法布雷医药公司 | 抗体-药物-缀合物和其用于治疗癌症的用途 |
| PT3134438T (pt) | 2014-04-25 | 2020-12-31 | Pf Medicament | Anticorpo igf-1r e sua utilização como veículo de endereçamento para o tratamento de cancro |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| PL3137502T3 (pl) | 2014-04-27 | 2021-03-08 | Famewave Ltd. | Humanizowane przeciwciała przeciwko CEACAM1 |
| WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
| TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
| EP3598980A3 (en) | 2014-06-26 | 2020-04-15 | Yale University | Compositions and methods to regulate renalase in the treatment of diseases and disorders |
| CN105315375B (zh) | 2014-07-17 | 2021-04-23 | 恺兴生命科技(上海)有限公司 | 靶向cld18a2的t淋巴细胞及其制备方法和应用 |
| ES2825708T3 (es) | 2014-07-17 | 2021-05-17 | Univ Pennsylvania | Métodos para usar exosomas para monitorizar el estado de órgano trasplantado |
| US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
| EP3201228A2 (en) | 2014-09-30 | 2017-08-09 | Neurimmune Holding AG | Human-derived anti-dipeptide repeats (dprs) antibody |
| EP3201226A2 (en) | 2014-10-03 | 2017-08-09 | Massachusetts Institute of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| EP3204516B1 (en) | 2014-10-06 | 2023-04-26 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| WO2016057651A1 (en) | 2014-10-09 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Multiple-variable il-2 dose regimen for treating immune disorders |
| EP3220900B1 (en) | 2014-11-21 | 2020-09-23 | University of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
| WO2016087889A1 (en) | 2014-12-03 | 2016-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers |
| US20180031579A1 (en) | 2015-02-12 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| EP3265825A4 (en) | 2015-03-06 | 2018-08-08 | Dana-Farber Cancer Institute, Inc. | Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| EP3271397B1 (en) | 2015-03-18 | 2021-03-03 | The Johns Hopkins University | Inhibitory monoclonal antibody targeting potassium channel kcnk9 |
| ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
| EP3277309A1 (en) | 2015-04-03 | 2018-02-07 | Alienor Farma | Monoclonal antibody to human line-1 orf2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject |
| ES2841437T3 (es) | 2015-04-13 | 2021-07-08 | Inst Nat Sante Rech Med | Métodos y composiciones farmacéuticas para el tratamiento de enfermedades hemorrágicas |
| JP2018519248A (ja) | 2015-04-22 | 2018-07-19 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｔｈ１７媒介性疾患の処置のための方法及び医薬組成物 |
| WO2016193299A1 (en) | 2015-06-01 | 2016-12-08 | Medigene Immunotherapies Gmbh | T cell receptor library |
| EA201792661A1 (ru) | 2015-06-01 | 2018-05-31 | Медиджин Иммьюнотерапиз Гмбх | Способ получения антител против т-клеточного рецептора |
| MX2017015619A (es) | 2015-06-01 | 2018-08-15 | Medigene Immunotherapies Gmbh | Anticuerpos especificos de receptor de celulas t. |
| EP3954394A1 (en) | 2015-06-19 | 2022-02-16 | Centurion BioPharma Corporation | Delivery systems for controlled drug release |
| US20180161429A1 (en) | 2015-06-26 | 2018-06-14 | Beth Israel Deaconess Medical Center Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
| KR20180021723A (ko) | 2015-06-29 | 2018-03-05 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 선택적 제조 방법 |
| CN107921128B (zh) | 2015-08-05 | 2022-04-26 | 詹森生物科技公司 | 抗cd154抗体及其使用方法 |
| EP3350212A1 (en) | 2015-09-18 | 2018-07-25 | INSERM - Institut National de la Santé et de la Recherche Médicale | T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes |
| ES2940360T3 (es) | 2015-09-22 | 2023-05-05 | Inst Nat Sante Rech Med | Polipéptidos capaces de inhibir la unión entre leptina y neuropilina-1 |
| TWI751979B (zh) | 2015-09-24 | 2022-01-11 | 日商第一三共股份有限公司 | 抗ｇａｒｐ抗體 |
| AU2016329057A1 (en) | 2015-09-30 | 2018-04-12 | Janssen Biotech, Inc. | Antagonistic antibodies specifically binding human CD40 and methods of use |
| JP6857360B2 (ja) | 2015-10-08 | 2021-04-14 | 国立大学法人東海国立大学機構 | キメラ抗原受容体を発現する遺伝子改変ｔ細胞の調製方法 |
| WO2017064716A1 (en) | 2015-10-13 | 2017-04-20 | Rappaport Family Institute For Research | Heparanase-neutralizing monoclonal antibodies |
| EP3362082A1 (en) | 2015-10-16 | 2018-08-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
| CN108650882B (zh) | 2015-10-26 | 2021-09-17 | 皮埃尔法布雷医药公司 | 用于治疗表达igf-1r的癌症的组合物 |
| US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
| ITUB20155272A1 (it) | 2015-11-02 | 2017-05-02 | Scuola Normale Superiore | Intracellular antibody |
| US10894830B2 (en) | 2015-11-03 | 2021-01-19 | Janssen Biotech, Inc. | Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses |
| EP3371222A1 (en) | 2015-11-03 | 2018-09-12 | GlycoMimetics, Inc. | Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same |
| ITUB20155097A1 (it) | 2015-11-05 | 2017-05-05 | Biouniversa Srl | Anticorpi umanizzati anti-BAG3 |
| EP3386542B1 (en) | 2015-12-10 | 2020-11-18 | Katholieke Universiteit Leuven | Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device |
| KR20180087430A (ko) | 2015-12-17 | 2018-08-01 | 얀센 바이오테크 인코포레이티드 | Hla-dr에 특이적으로 결합하는 항체 및 이의 용도 |
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| JP6697562B2 (ja) | 2015-12-23 | 2020-05-20 | メディジーン イミュノテラピーズ ゲーエムベーハー | 樹状細胞組成物 |
| US20190011449A1 (en) | 2015-12-31 | 2019-01-10 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating gastric cancer |
| EA037015B1 (ru) | 2015-12-31 | 2021-01-27 | Прогастрин Э Кансер С.А Р.Л. | Применение и способ для профилактики или лечения рака яичников с использованием композиции, содержащей прогастринсвязывающее антитело |
| JP7018885B2 (ja) | 2015-12-31 | 2022-02-14 | プロガストリン、エ、カンセル、エス、アー エル、エル | 食道癌の検出および治療のための組成物および方法 |
| EP3202788A1 (en) | 2016-02-05 | 2017-08-09 | MediaPharma S.r.l. | Endosialin-binding antibody |
| EP3205663A1 (en) | 2016-02-15 | 2017-08-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for inhibiting gene expression |
| WO2017140684A2 (en) | 2016-02-15 | 2017-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction |
| IL296874A (en) | 2016-03-01 | 2022-11-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Antibodies specific for the human poliovirus receptor |
| US11340233B2 (en) | 2016-03-07 | 2022-05-24 | Pierre Fabre Medicament | Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples |
| US11921116B2 (en) | 2016-03-09 | 2024-03-05 | Memorial Sloan Kettering Cancer Center | Enigma and CDH18 as companion diagnostics for CDK4 inhibitors |
| FI3779447T3 (fi) | 2016-03-15 | 2023-04-21 | Inst Nat Sante Rech Med | Menetelmä syöpään sairastuneen potilaan antitumoraalisen CD8+T -solun vasteen aktivoimiseen |
| WO2017158396A1 (en) | 2016-03-16 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cytidine deaminase inhibitors for the treatment of pancreatic cancer |
| EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
| CN111363041B (zh) | 2016-03-23 | 2022-02-22 | 苏州创胜医药集团有限公司 | 新型抗-pd-l1抗体 |
| SG10202009423QA (en) | 2016-03-28 | 2020-11-27 | Incyte Corp | Pyrrolotriazine compounds as tam inhibitors |
| ITUA20162242A1 (it) | 2016-04-01 | 2017-10-01 | St Biochimico Italiano Giovanni Lorenzini Spa | Un nuovo anticorpo anti-erbb2 |
| EP3445785B1 (en) | 2016-04-18 | 2022-06-22 | Faron Pharmaceuticals OY | Humanized anti clever-1 antibodies and their use |
| EP3452512B1 (en) | 2016-05-03 | 2023-03-08 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of tissue lesions |
| US11384140B2 (en) | 2016-05-11 | 2022-07-12 | Amgen Inc. | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors |
| JP2019516799A (ja) | 2016-05-20 | 2019-06-20 | カール、クリストフＫＡＲＬ， Ｃｈｒｉｓｔｏｐｈ | 骨代謝の障害および低カルシウム血症などの治療誘発性副作用の処置および／または予防に適した、抗ｒａｎｋｌ抗体、カルシウムおよびビタミンｄを含む薬学的組成物 |
| WO2017202814A1 (en) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons |
| WO2017202813A1 (en) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections |
| WO2017211900A1 (en) | 2016-06-07 | 2017-12-14 | Max-Delbrück-Centrum für Molekulare Medizin | Chimeric antigen receptor and car-t cells that bind bcma |
| GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| CA3027350A1 (en) | 2016-07-06 | 2018-01-11 | Prothena Biosciences Limited | Assay for detecting total and s129 phosphorylated alpha-synuclein |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| EP3487880A1 (en) | 2016-07-25 | 2019-05-29 | Biogen MA Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
| EP3491387A1 (en) | 2016-07-28 | 2019-06-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods of treatement of cancer disease by targetting tumor associated macrophage |
| US10669344B2 (en) | 2016-08-12 | 2020-06-02 | Janssen Biotech, Inc. | Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions |
| MA45941A (fr) | 2016-08-12 | 2019-06-19 | Janssen Biotech Inc | Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation |
| WO2018057618A1 (en) | 2016-09-20 | 2018-03-29 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators |
| BR112019005247A2 (pt) | 2016-10-07 | 2019-06-04 | Daiichi Sankyo Co Ltd | terapia para o câncer resistente a fármacos por meio de administração de conjugado de anticorpo anti-her2/fármaco |
| JPWO2018070390A1 (ja) | 2016-10-12 | 2019-08-22 | 第一三共株式会社 | 抗ｒｏｂｏ４抗体と他剤を含む組成物 |
| CA3040189A1 (en) | 2016-10-13 | 2018-04-19 | Massachusetts Institute Of Technology | Antibodies that bind zika virus envelope protein and uses thereof |
| IT201600111877A1 (it) | 2016-11-07 | 2018-05-07 | Biouniversa Srl | Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use |
| UA126388C2 (uk) | 2016-11-18 | 2022-09-28 | Астеллас Фарма Інк. | Fab-фрагмент антитіла до muc1 людини |
| CA3046293A1 (en) | 2016-12-12 | 2018-06-21 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| WO2018110555A1 (ja) | 2016-12-13 | 2018-06-21 | アステラス製薬株式会社 | 抗ヒトｃｄ７３抗体 |
| US10836818B2 (en) | 2016-12-15 | 2020-11-17 | The National Institute For Biotechnology I | Anti-PCNA monoclonal antibodies and use thereof |
| IL267567B1 (en) | 2016-12-22 | 2024-04-01 | Daiichi Sankyo Co Ltd | Anti-CD3 antibody - for use in treating or preventing cancer and molecules containing the antibody |
| US20180179490A1 (en) | 2016-12-27 | 2018-06-28 | Miltenyi Biotec Gmbh | CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS |
| US11773182B2 (en) | 2017-01-05 | 2023-10-03 | The Johns Hopkins University | Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA) |
| WO2018135501A1 (ja) | 2017-01-17 | 2018-07-26 | 第一三共株式会社 | 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体－薬物コンジュゲート |
| WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
| KR20190133160A (ko) | 2017-02-07 | 2019-12-02 | 다이이찌 산쿄 가부시키가이샤 | 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자 |
| EP3363459A1 (en) | 2017-02-17 | 2018-08-22 | Alexander Klimka | Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis |
| CA3092434A1 (en) | 2017-02-27 | 2018-08-30 | Caerus Therapeutics, Inc. | Compositions of a novel anti-human ceacam6 antibody and uses thereof |
| CA3053749A1 (en) | 2017-02-28 | 2018-09-07 | Kinki University | Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate |
| WO2018166495A1 (en) | 2017-03-15 | 2018-09-20 | Tsinghua University | Novel anti-trkb antibodies |
| JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| TWI782000B (zh) | 2017-03-30 | 2022-11-01 | 日商第一三共股份有限公司 | 抗ｇｐｒ２０抗體、其製造方法及其應用 |
| KR102351556B1 (ko) | 2017-03-30 | 2022-01-14 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 프로가스트린 결합 분자를 사용하는 전립선암의 검출 및 치료를 위한 조성물 및 방법 |
| KR102616819B1 (ko) | 2017-03-30 | 2023-12-21 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 폐암을 치료하기 위한 조성물 및 방법 |
| US10722589B2 (en) | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
| WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| WO2018189403A1 (en) | 2017-04-14 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancer |
| WO2018209301A1 (en) | 2017-05-11 | 2018-11-15 | Cytodyn Inc. | Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents |
| TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
| KR20200014414A (ko) | 2017-06-05 | 2020-02-10 | 얀센 바이오테크 인코포레이티드 | Pd-1과 특이적으로 결합하는 항체 및 사용 방법 |
| WO2018226685A2 (en) | 2017-06-06 | 2018-12-13 | Dana-Farber Cancer Institute, Inc. | Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways |
| WO2019005503A1 (en) | 2017-06-29 | 2019-01-03 | Rutgers, The State University Of New Jersey | COMPOSITIONS AND METHODS TARGETING G12 SIGNALING FOR BRONCHODILATORY THERAPY |
| US20200115446A1 (en) | 2017-06-30 | 2020-04-16 | National University Corporation Hokkaido University | Pediatric osteoporosis drug that does not cause growth disorder |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| WO2019018744A1 (en) | 2017-07-21 | 2019-01-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS |
| CN111051513A (zh) | 2017-07-27 | 2020-04-21 | 第一三共株式会社 | 抗cd147抗体 |
| WO2019020734A1 (en) | 2017-07-28 | 2019-01-31 | Biouniversa S.R.L. | ANTI-BAG3 ANTIBODIES AS THERAPEUTIC REAGENTS IN CARDIOVASCULAR DISEASES |
| CN110945023B (zh) | 2017-07-31 | 2023-08-18 | 豪夫迈·罗氏有限公司 | 基于三维结构的人源化方法 |
| EP3444272A1 (en) | 2017-08-17 | 2019-02-20 | International-Drug-Development-Biotech | Treatment of ck8 positive cancers in relation with k-ras gene status |
| CN111094349A (zh) | 2017-08-23 | 2020-05-01 | ***-德布鲁克-分子医学中心亥姆霍兹联合会 | 嵌合抗原受体和结合cxcr5的car-t细胞 |
| KR20200044044A (ko) | 2017-08-23 | 2020-04-28 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 제제 및 그 동결 건조 방법 |
| CN117838881A (zh) | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
| JP7366745B2 (ja) | 2017-08-31 | 2023-10-23 | 第一三共株式会社 | 抗体－薬物コンジュゲートの改良製造方法 |
| US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
| TW202404648A (zh) | 2017-09-29 | 2024-02-01 | 日商第一三共股份有限公司 | 抗體－吡咯并苯二氮呯衍生物複合體 |
| CN111065400A (zh) | 2017-10-03 | 2020-04-24 | 公益财团法人东京都医学总合研究所 | 抗流感药物 |
| EP3693012A4 (en) | 2017-10-05 | 2021-07-21 | Daiichi Sankyo Company, Limited | COMPOSITION FOR DEPLOYMENT OF T-CYTOTOXIC LYMPHOCYTES |
| KR101966362B1 (ko) * | 2017-10-20 | 2019-04-05 | 주식회사 녹십자 | 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| WO2019094595A2 (en) | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
| CN111712263A (zh) | 2017-11-30 | 2020-09-25 | 森托瑞恩生物制药公司 | 基于美登木素生物碱的药物递送*** |
| WO2019108974A1 (en) | 2017-11-30 | 2019-06-06 | Centurion Biopharma Corporation | Albumin-binding prodrugs of auristatin e derivatives |
| WO2019106126A1 (en) | 2017-12-01 | 2019-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mdm2 modulators for the diagnosis and treatment of liposarcoma |
| WO2019110662A1 (en) | 2017-12-05 | 2019-06-13 | Progastrine Et Cancers S.À R.L. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
| WO2019121872A1 (en) | 2017-12-20 | 2019-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of liver cancer |
| US20190225689A1 (en) | 2018-01-22 | 2019-07-25 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-pd-1 antibodies |
| TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ｅｃｓ前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
| WO2019155474A1 (en) | 2018-02-12 | 2019-08-15 | Hadasit Medical Research Services & Development Ltd. | Modulation of slamf6 splice variants for cancer therapy |
| WO2019158512A1 (en) | 2018-02-13 | 2019-08-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the prognosis and the treatment of glioblastoma |
| EP3759492A1 (en) | 2018-02-27 | 2021-01-06 | ECS-Progastrin SA | Progastrin as a biomarker for immunotherapy |
| CR20200441A (es) | 2018-02-27 | 2021-03-15 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b |
| AU2019231380A1 (en) | 2018-03-05 | 2020-09-24 | Daiichi Sankyo Company, Limited | Pharmaceutical composition for treating or preventing heterotopic ossification |
| US20210047696A1 (en) | 2018-03-28 | 2021-02-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| JP2021521445A (ja) | 2018-04-13 | 2021-08-26 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前立腺癌又は乳癌を患っている患者の転帰を予測するための及び処置のための方法 |
| SG11202009626QA (en) | 2018-04-20 | 2020-10-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor and car-t cells that bind a herpes virus antigen |
| WO2019207066A1 (en) | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of sjögren's syndrome |
| WO2019211370A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| WO2019211369A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| EP3790900A1 (en) | 2018-05-09 | 2021-03-17 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Antibodies specific to human nectin4 |
| SG11202011163SA (en) | 2018-05-11 | 2020-12-30 | Astellas Pharma Inc | Nucleic acid for treating mite allergy |
| SG11202011166UA (en) | 2018-05-11 | 2020-12-30 | Astellas Pharma Inc | Nucleic acid for treating crustacean allergy |
| EP3795590A4 (en) | 2018-05-17 | 2022-05-04 | Astellas Pharma Inc. | COMPLEX HAVING ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGAND |
| MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
| JOP20200303A1 (ar) | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | عوامل ربط psma واستخداماتها |
| PE20210634A1 (es) | 2018-05-24 | 2021-03-23 | Janssen Biotech Inc | Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos |
| JOP20200302A1 (ar) | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | الأجسام المضادة لـ cd3 واستخداماتها |
| SG11202011243XA (en) | 2018-05-28 | 2020-12-30 | Daiichi Sankyo Co Ltd | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate |
| TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| SG11202010939WA (en) | 2018-05-31 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-human tlr7 antibody |
| CA3098420A1 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
| WO2019234099A1 (en) | 2018-06-06 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction |
| WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
| CN112955464A (zh) | 2018-06-20 | 2021-06-11 | 因赛特公司 | 抗pd-1抗体及其用途 |
| TW202016144A (zh) | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | 包括cd3抗原結合片段之組成物及其用途 |
| US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
| WO2020007898A1 (en) | 2018-07-04 | 2020-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating brain injury or neurodegenerative disease |
| JPWO2020022363A1 (ja) | 2018-07-25 | 2021-08-02 | 第一三共株式会社 | 抗体−薬物コンジュゲートの効果的な製造方法 |
| EP3831853A4 (en) | 2018-07-27 | 2022-06-01 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT |
| WO2020022499A1 (ja) | 2018-07-27 | 2020-01-30 | 国立大学法人大阪大学 | 老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物 |
| SG11202100947SA (en) | 2018-07-31 | 2021-03-30 | Daiichi Sankyo Co Ltd | Treatment of metastatic brain tumor by administration of antibody-drug conjugate |
| JP7458981B2 (ja) | 2018-08-06 | 2024-04-01 | 第一三共株式会社 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| SG11202101526YA (en) | 2018-09-06 | 2021-03-30 | Daiichi Sankyo Co Ltd | Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof |
| CA3113207A1 (en) | 2018-09-20 | 2020-03-26 | Daiichi Sankyo Company, Limited | Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate |
| US20230038521A1 (en) | 2018-09-21 | 2023-02-09 | National University Corporation Tokyo Medical An D Dental University | Human Monoclonal Antibody Binding Specifically to Human Hmgb1, and Pharmaceutical Composition for Treating or Preventing Alzheimer's Disease Containing Said Human Monoclonal Antibody |
| CN113453724A (zh) | 2018-09-27 | 2021-09-28 | 皮埃尔法布雷医药公司 | 基于磺酰基马来酰亚胺的连接子和相应的偶联物 |
| AU2019350466A1 (en) | 2018-09-28 | 2021-04-29 | Pierre Fabre Medicament | New immunocytokines for the treatment of cancer |
| JP7374544B2 (ja) | 2018-10-10 | 2023-11-07 | アステラス製薬株式会社 | 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物 |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| EP3867269A1 (en) | 2018-10-18 | 2021-08-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor |
| TW202035459A (zh) | 2018-10-31 | 2020-10-01 | 日商安斯泰來製藥股份有限公司 | 抗人類Fn14抗體 |
| EP3880706A1 (en) | 2018-11-12 | 2021-09-22 | MediaPharma S.r.l. | Bispecific antibodies directed against human 90k and either endosialin or her3 |
| CN113166764A (zh) | 2018-11-14 | 2021-07-23 | 第一三共株式会社 | 抗cdh6抗体-吡咯并苯并二氮杂环庚三烯衍生物缀合物 |
| AU2019396895A1 (en) | 2018-12-11 | 2021-07-08 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with PARP inhibitor |
| CA3124408A1 (en) | 2018-12-21 | 2020-06-25 | Aim Immunotech Inc. | Compositions and methods for cancer therapy |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| KR20210113201A (ko) | 2019-01-07 | 2021-09-15 | 아스텔라스세이야쿠 가부시키가이샤 | 배위자 및 CEACAM5 항체 Fab 프래그먼트를 포함하는 복합체 |
| TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | ***新抗原及其用途 |
| US20220112283A1 (en) | 2019-01-13 | 2022-04-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human nectin-2 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶 |
| EP3917515A1 (en) | 2019-01-29 | 2021-12-08 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Treating the causative agent in adhesiogenesis |
| KR20210126078A (ko) | 2019-02-13 | 2021-10-19 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 항-말초 림프절 어드레신 항체 및 그의 용도 |
| WO2020178193A1 (en) | 2019-03-01 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment of sarcoidosis |
| EP3942026A1 (en) | 2019-03-22 | 2022-01-26 | Université de Paris | New inhibitors of lrrk2/pp1 interaction |
| WO2020196474A1 (ja) | 2019-03-25 | 2020-10-01 | 第一三共株式会社 | 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート |
| BR112021017616A2 (pt) | 2019-03-25 | 2021-11-09 | Daiichi Sankyo Co Ltd | Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina |
| AU2020247119A1 (en) | 2019-03-25 | 2021-09-23 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Enhancement of cytolytic T-cell activity by inhibiting EBAG9 |
| JPWO2020196712A1 (no) | 2019-03-27 | 2020-10-01 | ||
| US20220193064A1 (en) | 2019-04-01 | 2022-06-23 | Chiome Bioscience Inc. | Medicament for treating cancer |
| WO2020206033A1 (en) | 2019-04-02 | 2020-10-08 | Kenjockety Biotechnology, Inc. | Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
| EP3956022A1 (en) | 2019-04-19 | 2022-02-23 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti- psma/cd3 antibody |
| WO2020229546A1 (en) | 2019-05-14 | 2020-11-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof |
| CA3142119A1 (en) | 2019-05-29 | 2020-12-03 | Daiichi Sankyo Company, Limited | Dosage of an antibody-drug conjugate for treating cancer |
| TW202115114A (zh) | 2019-06-24 | 2021-04-16 | 瑞士商諾華公司 | 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法 |
| JP2022541332A (ja) | 2019-07-26 | 2022-09-22 | ヤンセン バイオテツク，インコーポレーテツド | カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用 |
| US20220267453A1 (en) | 2019-07-26 | 2022-08-25 | Saitama Medical University | Antibody recognizing extracellular region of alk2/acvr1 |
| WO2021019706A1 (ja) | 2019-07-31 | 2021-02-04 | 国立大学法人信州大学 | Ｃａｒ発現免疫細胞を含む細胞集団の製造方法 |
| AU2020319875A1 (en) | 2019-08-01 | 2022-02-17 | Incyte Corporation | A dosing regimen for an IDO inhibitor |
| BR112022001037A2 (pt) | 2019-08-02 | 2022-06-07 | Cytodyn Inc | Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5 |
| KR102433076B1 (ko) | 2019-08-12 | 2022-08-19 | 비온드 바이오로직스 엘티디 | Ilt2에 대한 항체 및 이의 용도 |
| EP3792632A1 (en) | 2019-09-16 | 2021-03-17 | Vito NV | Immunotherapy markers |
| CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| EP4034151A1 (en) | 2019-09-27 | 2022-08-03 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of müllerian inhibiting substance inhibitors for treating cancer |
| WO2021059075A1 (en) | 2019-09-27 | 2021-04-01 | Janssen Biotech, Inc. | Anti-ceacam antibodies and uses thereof |
| CN114630679A (zh) | 2019-10-25 | 2022-06-14 | 第一三共株式会社 | 抗garp抗体和免疫调节剂的组合 |
| US20210147526A1 (en) | 2019-11-15 | 2021-05-20 | Pliant Therapeutics, Inc. | Compositions and methods for activation of integrins |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| US20230022143A1 (en) * | 2019-12-10 | 2023-01-26 | CCOA Therapeutics Inc. | Humanized anti-glycoprotein ib alpha (gpibalpha) antibodies |
| US11396541B2 (en) | 2019-12-20 | 2022-07-26 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 P19 antibodies and methods of use thereof |
| AU2020417813A1 (en) | 2020-01-03 | 2022-08-25 | Incyte Corporation | Combination therapy comprising A2A/A2B and PD-1/PD-L1 inhibitors |
| WO2021140173A1 (en) | 2020-01-10 | 2021-07-15 | Biouniversa S.R.L. | Methods and uses for treating fibrotic solid tumors with bags inhibitors |
| WO2021156329A1 (en) | 2020-02-05 | 2021-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of treatment of cancer disease by targeting an epigenetic factor |
| TW202140012A (zh) | 2020-02-12 | 2021-11-01 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑 |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| AU2021229611A1 (en) | 2020-03-03 | 2022-10-27 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| CN115697343A (zh) | 2020-03-06 | 2023-02-03 | 因赛特公司 | 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法 |
| TW202140044A (zh) | 2020-03-06 | 2021-11-01 | 日商第一三共股份有限公司 | 含有新穎環狀雙核苷酸衍生物之抗體藥物共軛物 |
| WO2021183207A1 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER |
| KR20230051617A (ko) | 2020-03-13 | 2023-04-18 | 얀센 바이오테크 인코포레이티드 | Siglec-3/cd33을 결합시키기 위한 물질 및 방법 |
| US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
| EP4130036A4 (en) | 2020-03-30 | 2024-05-15 | Nat Cancer Ct | ANTIBODY-DRUG CONJUGATE |
| EP3889183A1 (en) | 2020-04-01 | 2021-10-06 | Pierre Fabre Medicament | A protein complex comprising an immunocytokine |
| EP4132568A1 (en) | 2020-04-06 | 2023-02-15 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections |
| US20230174670A1 (en) | 2020-05-14 | 2023-06-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof |
| JP2023526529A (ja) | 2020-05-19 | 2023-06-21 | アンスティテュ・クリー | サイトカイン放出症候群の診断及び処置の方法 |
| AU2021281828A1 (en) | 2020-05-27 | 2023-02-02 | Arialys Therapeutics, Inc. | Anti-human NR1 antibody derivative |
| MX2022014938A (es) | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas. |
| AU2021283080A1 (en) | 2020-06-04 | 2022-12-15 | Kenjockety Biotechnology, Inc. | ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
| WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
| CN116194109A (zh) | 2020-06-24 | 2023-05-30 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和atm抑制剂的组合 |
| IL299368A (en) | 2020-06-24 | 2023-02-01 | Astrazeneca Uk Ltd | A combination of an antibody-drug conjugate and an ATR inhibitor |
| TW202216207A (zh) | 2020-06-24 | 2022-05-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及cdk9抑制劑之組合 |
| WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
| WO2021260139A1 (en) | 2020-06-25 | 2021-12-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of treatment and diagnostic of pathological conditions associated with intense stress |
| US20230277679A1 (en) | 2020-07-17 | 2023-09-07 | Daiichi Sankyo Company, Limited | Method for producing antibody-drug conjugate |
| US20230293714A1 (en) | 2020-07-20 | 2023-09-21 | Daiichi Sankyo Company, Limited | Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor |
| CA3190307A1 (en) | 2020-07-29 | 2022-02-03 | Janssen Biotech, Inc. | Proteins comprising hla-g antigen binding domains and their uses |
| RU2764216C1 (ru) * | 2020-08-10 | 2022-01-14 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" | Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения |
| IL300588A (en) | 2020-08-12 | 2023-04-01 | Biond Biologics Ltd | Antibodies against ILT-2 and their use |
| EP4199958A1 (en) | 2020-08-24 | 2023-06-28 | Charité - Universitätsmedizin Berlin | Chimeric antigen receptor (car)-expressing cells recognizing cea |
| WO2022043315A1 (en) | 2020-08-24 | 2022-03-03 | Charité - Universitätsmedizin Berlin | A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 |
| WO2022051591A2 (en) | 2020-09-04 | 2022-03-10 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
| EP4210722A1 (en) | 2020-09-07 | 2023-07-19 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods of treatment of inflammatory bowel diseases |
| IL301265A (en) | 2020-09-12 | 2023-05-01 | Astrazeneca Uk Ltd | Scoring method for anti-HER2 antibody-drug conjugate therapy |
| JPWO2022075482A1 (no) | 2020-10-05 | 2022-04-14 | ||
| AU2021356762A1 (en) | 2020-10-09 | 2023-05-25 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| AR123767A1 (es) | 2020-10-13 | 2023-01-11 | Janssen Biotech Inc | Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii |
| WO2022084399A1 (en) | 2020-10-21 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | C-terminal sparc fragments for treating cancer |
| WO2022084915A1 (en) | 2020-10-22 | 2022-04-28 | Janssen Biotech, Inc. | Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses |
| WO2022097090A1 (en) | 2020-11-05 | 2022-05-12 | Novartis Ag | Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors |
| KR20230113564A (ko) | 2020-11-06 | 2023-07-31 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 다낭성 난소 증후군(pcos)의 진단 및 치료 방법 |
| JPWO2022102634A1 (no) | 2020-11-11 | 2022-05-19 | ||
| CA3198382A1 (en) | 2020-11-12 | 2022-05-19 | Michiko Yamato | Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate |
| US11897954B2 (en) | 2020-11-16 | 2024-02-13 | Astellas Pharma Inc. | Anti-TSPAN8/anti-CD3 bispecific antibody and anti-TSPAN8 antibody |
| WO2022112469A1 (en) | 2020-11-27 | 2022-06-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and monitoring of toxic epidermal necrolysis |
| WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| US20220241411A1 (en) | 2020-11-30 | 2022-08-04 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| EP4260872A1 (en) | 2020-12-09 | 2023-10-18 | National University Corporation Tokyo Medical and Dental University | Agent for preventing or treating frontotemporal lobar degeneration |
| CA3207066A1 (en) | 2020-12-29 | 2022-07-07 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
| WO2022153194A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
| WO2022153212A1 (en) | 2021-01-13 | 2022-07-21 | Axon Neuroscience Se | Antibodies neutralizing sars-cov-2 |
| TW202245844A (zh) | 2021-01-13 | 2022-12-01 | 紀念斯隆凱特琳癌症中心 | 抗dll3抗體-藥物結合物 |
| AU2022214491A1 (en) | 2021-01-28 | 2023-09-14 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
| US20240141060A1 (en) | 2021-01-29 | 2024-05-02 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
| TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體－免疫賦活化劑共軛物之新穎製造方法 |
| JP2024507124A (ja) | 2021-02-11 | 2024-02-16 | ネクチン セラピューティクス リミテッド | Ｃｄ１１２ｒに対する抗体およびその使用 |
| AU2022219517A1 (en) | 2021-02-12 | 2023-07-13 | Boehringer Ingelheim International Gmbh | Complement c3 antigen binding proteins |
| US20220378929A1 (en) | 2021-02-25 | 2022-12-01 | MediBoston Limted | Anti-her2 antibody-drug conjugates and uses thereof |
| CN117425674A (zh) | 2021-03-02 | 2024-01-19 | 丹娜法伯癌症研究院 | 治疗红细胞疾患的方法 |
| JPWO2022191313A1 (no) | 2021-03-12 | 2022-09-15 | ||
| EP4305064A1 (en) | 2021-03-12 | 2024-01-17 | Fibrosys S.r.l. | Monoclonal antibodies for the treatment of viral infections |
| AU2022244453A1 (en) | 2021-03-24 | 2023-11-09 | Janssen Biotech, Inc. | Antibody targeting cd22 and cd79b |
| US20240166731A1 (en) | 2021-03-26 | 2024-05-23 | Janssen Biotech, Inc. | Humanized antibodies against paired helical filament tau and uses thereof |
| WO2022218998A1 (en) | 2021-04-13 | 2022-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating hepatitis b and d virus infection |
| EP4323402A1 (en) | 2021-04-14 | 2024-02-21 | Villaris Therapeutics, Inc. | Anti-cd122 antibodies and uses thereof |
| CA3217637A1 (en) | 2021-04-22 | 2022-10-27 | Astellas Pharma Inc. | Anti-cldn4/anti-cd137 bispecific antibody |
| WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
| CN113361141B (zh) * | 2021-07-11 | 2022-02-18 | 西南石油大学 | 一种dna图谱算法的改进试验方法 |
| US11987641B2 (en) | 2021-08-27 | 2024-05-21 | Janssen Biotech, Inc. | Anti-PSMA antibodies and uses thereof |
| CA3231632A1 (en) | 2021-09-15 | 2023-03-23 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer |
| WO2023041744A1 (en) | 2021-09-17 | 2023-03-23 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
| WO2023046322A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceutica Nv | Proteins comprising cd20 binding domains, and uses thereof |
| WO2023052541A1 (en) | 2021-09-30 | 2023-04-06 | Imcheck Therapeutics | Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy |
| TW202330041A (zh) | 2021-10-18 | 2023-08-01 | 日商第一三共股份有限公司 | 抗cd37抗體-藥物結合物 |
| AU2022378932A1 (en) | 2021-10-27 | 2024-05-02 | Assistance Publique Hopitaux De Marseille | Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders |
| EP4177266A1 (en) | 2021-11-05 | 2023-05-10 | Katholieke Universiteit Leuven | Neutralizing anti-sars-cov-2 human antibodies |
| TW202329936A (zh) | 2021-11-18 | 2023-08-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物與parp1選擇性抑制劑之組合 |
| WO2023089032A1 (en) | 2021-11-19 | 2023-05-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
| WO2023097119A2 (en) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
| WO2023099763A1 (en) | 2021-12-03 | 2023-06-08 | Institut Curie | Sirt6 inhibitors for use in treating resistant hrd cancer |
| WO2023105528A1 (en) | 2021-12-12 | 2023-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to ceacam1 |
| US20230357392A1 (en) | 2021-12-22 | 2023-11-09 | Morphosys Ag | Treatment Paradigm for an Anti-CD19 Antibody Therapy |
| TW202333800A (zh) | 2021-12-28 | 2023-09-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及rasg12c抑制劑之組合 |
| TW202339805A (zh) | 2021-12-28 | 2023-10-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atr抑制劑之組合 |
| WO2023152581A1 (en) | 2022-02-09 | 2023-08-17 | Janssen Biotech, Inc. | Method of treating cancer with psmaxcd3 antibody |
| WO2023166081A1 (en) | 2022-03-02 | 2023-09-07 | Heidelberg Immunotherapeutics Gmbh | Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody |
| WO2023175614A1 (en) | 2022-03-15 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof |
| WO2023175483A1 (en) | 2022-03-16 | 2023-09-21 | Astrazeneca Uk Limited | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
| TW202400140A (zh) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
| TW202400650A (zh) | 2022-05-11 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體與cd47抑制劑之組合 |
| WO2023228095A1 (en) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
| WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
| WO2024023750A1 (en) | 2022-07-28 | 2024-02-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
| WO2024072893A1 (en) | 2022-09-28 | 2024-04-04 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
| WO2024074498A1 (en) | 2022-10-04 | 2024-04-11 | Imcheck Therapeutics | Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| JPS6033453B2 (ja) * | 1978-08-17 | 1985-08-02 | 富士電機株式会社 | 魚切断加工自動化装置 |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6014678A (ja) * | 1983-07-04 | 1985-01-25 | Taiheiyo Kogyo Kk | 電磁弁 |
| GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB2188941B (en) * | 1986-04-14 | 1990-06-06 | Bayer Ag | Monoclonal antibodies recognizing human interleukin-2-receptor |
| DK554986A (da) * | 1986-11-19 | 1988-07-18 | Novo Industri As | Human-human hybride cellelinier samt dermed producerede monoklonale cancerantistoffer |
| GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| CA1339198C (en) * | 1988-02-12 | 1997-08-05 | Gregory Paul Winter | Antibodies to the antigen campath-1 |
| JPH02503867A (ja) * | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | Ｉｌ‐２レセプター特異的キメラ抗体 |
| JP5598363B2 (ja) | 2011-02-15 | 2014-10-01 | ソニー株式会社 | 記憶装置およびその動作方法 |
-
1989
- 1989-11-27 IL IL162181A patent/IL162181A/en not_active IP Right Cessation
- 1989-12-27 IL IL92904A patent/IL92904A0/xx not_active IP Right Cessation
- 1989-12-28 DE DE122005000007C patent/DE122005000007I2/de active Active
- 1989-12-28 SI SI8912489A patent/SI8912489B/sl unknown
- 1989-12-28 DE DE68929061T patent/DE68929061T2/de not_active Expired - Lifetime
- 1989-12-28 ES ES95105609T patent/ES2136760T3/es not_active Expired - Lifetime
- 1989-12-28 EP EP04076438.3A patent/EP1491556B1/en not_active Expired - Lifetime
- 1989-12-28 DE DE19975047C patent/DE19975047I2/de active Active
- 1989-12-28 KR KR1019900701939A patent/KR0178385B1/ko not_active IP Right Cessation
- 1989-12-28 DE DE04076438.3T patent/DE04076438T1/de active Pending
- 1989-12-28 IE IE20000331A patent/IE20000331A1/en unknown
- 1989-12-28 DE DE68925536T patent/DE68925536T3/de not_active Expired - Lifetime
- 1989-12-28 JP JP2503677A patent/JP2828340B2/ja not_active Ceased
- 1989-12-28 EP EP10185689A patent/EP2341080A1/en not_active Withdrawn
- 1989-12-28 ES ES98204240.0T patent/ES2492815T3/es not_active Expired - Lifetime
- 1989-12-28 YU YU248989A patent/YU48700B/sh unknown
- 1989-12-28 DE DE200712000037 patent/DE122007000037I1/de active Pending
- 1989-12-28 MC MC@@@@D patent/MC2146A1/xx unknown
- 1989-12-28 PT PT92758A patent/PT92758B/pt active IP Right Grant
- 1989-12-28 DE DE68925536A patent/DE68925536D1/de not_active Expired - Lifetime
- 1989-12-28 CN CN89109618A patent/CN1057013C/zh not_active Expired - Lifetime
- 1989-12-28 EP EP04076439.1A patent/EP1477497B1/en not_active Expired - Lifetime
- 1989-12-28 DE DE122009000071C patent/DE122009000071I1/de active Pending
- 1989-12-28 DE DE98204240.0T patent/DE98204240T1/de active Pending
- 1989-12-28 EP EP95105609A patent/EP0682040B1/en not_active Revoked
- 1989-12-28 DE DE2000175005 patent/DE10075005I2/de active Active
- 1989-12-28 WO PCT/US1989/005857 patent/WO1990007861A1/en active IP Right Grant
- 1989-12-28 EP EP98204240.0A patent/EP0939127B1/en not_active Expired - Lifetime
- 1989-12-28 ZA ZA899956A patent/ZA899956B/xx unknown
- 1989-12-28 EP EP90903576A patent/EP0451216B9/en not_active Expired - Lifetime
- 1989-12-28 ES ES04076438.3T patent/ES2440825T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE122005000057C patent/DE122005000057I2/de active Active
- 1989-12-28 ES ES90903576T patent/ES2081974T5/es not_active Expired - Lifetime
- 1989-12-28 ES ES04076439.1T patent/ES2523810T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE2000175038 patent/DE10075038I2/de active Active
- 1989-12-28 AT AT95105609T patent/ATE183753T1/de not_active IP Right Cessation
- 1989-12-28 CA CA002006865A patent/CA2006865C/en not_active Expired - Lifetime
- 1989-12-28 DE DE04076439.1T patent/DE04076439T1/de active Pending
- 1989-12-28 AT AT90903576T patent/ATE133452T1/de active
- 1989-12-28 RU SU4895847/13A patent/RU2126046C1/ru active
- 1989-12-28 AU AU51532/90A patent/AU647383B2/en not_active Expired
- 1989-12-28 DE DE1989625536 patent/DE122006000036I1/de active Pending
- 1989-12-28 CA CA002328851A patent/CA2328851C/en not_active Expired - Lifetime
-
1990
- 1990-01-04 NZ NZ314793A patent/NZ314793A/xx unknown
- 1990-01-04 NZ NZ231984A patent/NZ231984A/en unknown
- 1990-01-17 DD DD90337159A patent/DD296964A5/de unknown
-
1991
- 1991-05-20 FI FI912436A patent/FI108797B/fi active Protection Beyond IP Right Term
- 1991-06-19 DK DK119191A patent/DK119191A/da not_active Application Discontinuation
- 1991-06-19 NO NO19912385A patent/NO310473B1/no not_active IP Right Cessation
- 1991-12-31 CZ CS914186A patent/CZ418691A3/cs unknown
-
1992
- 1992-01-20 BG BG95784A patent/BG61095B2/xx unknown
- 1992-09-26 HR HRP-2489/89A patent/HRP920500B1/xx not_active IP Right Cessation
-
1995
- 1995-06-16 HU HU95P/P00236P patent/HU211174A9/hu active Protection Beyond IP Right Term
-
1996
- 1996-04-13 SG SG1996007855A patent/SG78258A1/en unknown
-
1998
- 1998-01-12 JP JP00433498A patent/JP3604058B2/ja not_active Expired - Lifetime
- 1998-07-16 DK DK199800941A patent/DK174317B1/da not_active IP Right Cessation
- 1998-12-28 HK HK98115967A patent/HK1014718A1/xx not_active IP Right Cessation
-
1999
- 1999-07-02 LU LU90411C patent/LU90411I2/fr unknown
- 1999-07-14 NL NL990020C patent/NL990020I2/nl unknown
-
2000
- 2000-02-11 LU LU90528C patent/LU90528I2/fr unknown
- 2000-02-11 NL NL300005C patent/NL300005I2/nl unknown
- 2000-11-03 NL NL300023C patent/NL300023I2/nl unknown
- 2000-11-09 LU LU90676C patent/LU90676I2/fr unknown
-
2001
- 2001-12-17 NO NO2001026C patent/NO2001026I2/no unknown
- 2001-12-17 NO NO2001024C patent/NO2001024I1/no unknown
- 2001-12-17 NO NO2001025C patent/NO2001025I2/no unknown
-
2003
- 2003-01-20 JP JP2003011705A patent/JP2003245090A/ja not_active Withdrawn
- 2003-01-20 JP JP2003011706A patent/JP2003245091A/ja not_active Withdrawn
-
2005
- 2005-02-04 LU LU91139C patent/LU91139I2/fr unknown
- 2005-02-10 NL NL300173C patent/NL300173I2/nl unknown
- 2005-02-18 NO NO2005005C patent/NO2005005I2/no unknown
- 2005-12-02 LU LU91208C patent/LU91208I2/fr unknown
- 2005-12-07 NO NO2005026C patent/NO2005026I2/no unknown
- 2005-12-12 NL NL300213C patent/NL300213I2/nl unknown
-
2006
- 2006-08-07 NO NO2006009C patent/NO2006009I2/no unknown
- 2006-08-07 NL NL300239C patent/NL300239I2/nl unknown
- 2006-08-07 LU LU91272C patent/LU91272I2/fr unknown
-
2007
- 2007-03-02 JP JP2007053539A patent/JP2007145863A/ja not_active Withdrawn
- 2007-04-11 LU LU91333C patent/LU91333I2/fr unknown
- 2007-04-18 NL NL300279C patent/NL300279I2/nl unknown
- 2007-04-18 NO NO2007006C patent/NO2007006I2/no unknown
-
2009
- 2009-04-21 JP JP2009103471A patent/JP2009165488A/ja not_active Withdrawn
- 2009-11-12 NO NO2009026C patent/NO2009026I1/no unknown
- 2009-11-19 NL NL300426C patent/NL300426I1/nl unknown
- 2009-12-09 LU LU91627C patent/LU91627I2/fr unknown
-
2014
- 2014-09-17 FR FR14C0070C patent/FR14C0070I1/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO912385D0 (no) | Chimere immunoglobuliner som er spesifikke for p55 tac proteiner av il-2 reseptoren. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: TRASTUZUMAB ELLER FARMASOEYTISKE AKSEPTABLE SALTER DERAV; NAT. REG. NO/DATE: NO , EU/1/00/14 20000928; FIRST REG. NO/DATE: EP , EU/1/00/14 20000828 Spc suppl protection certif: 2001024 Filing date: 20011217 Extension date: 20141228 Effective date: 20031229 |
|
| SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: XOLAIR, 75 MG OG 150 MG, PULVER OG VAESKE TIL INJEKSJONSVAESKE, OPPLOESNING; NAT. REG. NO/DATE: EU/1/05/319/00-002/NO 20051025; FIRST REG. NO/DATE: EU , EU/1/05/319/00-002 20051025 Spc suppl protection certif: 2005026 Filing date: 20051207 Extension date: 20141228 |
|
| SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: TYSABRI; NAT. REG. NO/DATE: EU106346NO 20060627; FIRST REG. NO/DATE: EU , EU106346 20060627 Spc suppl protection certif: 2006009 Filing date: 20060807 Extension date: 20141228 |
|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: DACLIZUMAB; NAT. REG. NO/DATE: NO , 97-3585 19991126; FIRST REG. NO/DATE: EP , EU/1/99/09 19990226 Spc suppl protection certif: 2001026 Filing date: 20011217 Extension date: 20130303 |
|
| SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: LUCENTIS 10 MG/ML INJEKSJONSVAESKE, OPPLOSNING "NOVARTIS EUROPHARM" - 1 HETTEGLASS; NAT. REG. NO/DATE: EU106374001NO 20070207; FIRST REG. NO/DATE: LI , 57664 20060825 Spc suppl protection certif: 2007006 Filing date: 20070418 Extension date: 20141228 |
|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: AVASTIN, 25 MG/ML, KONSENTRAT TIL OPPLOSNING FOR INFUSJON, INTRAVENOS ANVENDELSE; NAT. REG. NO/DATE: EU/1/04/300/001/NO-002/NO 20050118; FIRST REG. NO/DATE: EU , EU/1/04/300/001-002 20050112 Spc suppl protection certif: 2005005 Filing date: 20050218 Extension date: 20141228 Free format text: PRODUCT NAME: XOLAIR, 75 MG OG 150 MG, PULVER OG VAESKE TIL INJEKSJONSVAESKE, OPPLOESNING; NAT. REG. NO/DATE: EU/1/05/319/00-002/NO 20051025; FIRST REG. NO/DATE: EU , EU/1/05/319/00-002 20051025 Spc suppl protection certif: 2005026 Filing date: 20051207 Extension date: 20141228 |
|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: LUCENTIS 10 MG/ML INJEKSJONSVAESKE, OPPLOSNING "NOVARTIS EUROPHARM" - 1 HETTEGLASS; NAT. REG. NO/DATE: EU106374001NO 20070207; FIRST REG. NO/DATE: LI , 57664 20060825 Spc suppl protection certif: 2007006 Filing date: 20070418 Extension date: 20141228 Free format text: PRODUCT NAME: TYSABRI; NAT. REG. NO/DATE: EU106346NO 20060627; FIRST REG. NO/DATE: EU , EU106346 20060627 Spc suppl protection certif: 2006009 Filing date: 20060807 Extension date: 20141228 |
|
| MK1K | Patent expired | ||
| SPCX | Expiry of an spc |
Spc suppl protection certif: 2005005 Effective date: 20141228 Spc suppl protection certif: 2001024 Effective date: 20141228 Spc suppl protection certif: 2006009 Effective date: 20141228 Spc suppl protection certif: 2007006 Effective date: 20141228 Spc suppl protection certif: 2005026 Effective date: 20141228 |